

BASO-THE ASSOCIATION FOR CANCER SURGERY

England & Wales · Charity number 1136067

Details

Status Registered

Legal form Charitable company

Company number [07225131](#)

Registered 2010-05-21

Register [View on the Charity Commission register](#)

Contact

Address Royal College Of Surgeons Of Englan
38-43 Lincoln's Inn Fields
London
WC2A 3PE

Phone 02078696854

Email admin@baso.org.uk

Website www.baso.org.uk

Activities

Objects: 1 TO ADVANCE THE SCIENCE, PRACTICE AND ART OF SURGICAL ONCOLOGY FOR THE BENEFIT OF PATIENTS WITH CANCER, AND2 TO ADVANCE RESEARCH, TRAINING AND EDUCATION IN SURGICAL ONCOLOGY FOR THE BENEFIT OF THE PUBLIC AND TO DISSEMINATE THE USEFUL RESULTS OF TH0AT RESEARCH SERVICES AND BY FACILITATING PARTNERSHIP AND THE COOPERATION IN THE VOLUNTARY SECTORB THE PREVENTION OR RELIEF OF POVERTY AND THE RELIEF OF THOSE IN NEED BY REASON OF YOUTH, AGE, FINANCIAL HARDSHIP OR OTHER DISADVANTAGE IN THE ADVANCEMENT OF EDUCATION'VOLUNTARY SECTOR' MEANS CHARITIES AND VOLUNTARY ORGANISATIONSA CHARITIES ARE ORGANISATIONS WHICH ARE ESTABLISHED FOR EXCLUSIVELY CHARITABLE PURPOSES IN ACCORDANCE WITH THE LAW OF ENGLAND AND WALESB VOLUNTARY ORGANISATIONS ARE INDEPENDENT ORGANISATIONS WHICH ARE ESTABLISHED FOR PURPOSES THAT ADD VALUE TO THE COMMUNITY AS A WHOLE OR A SIGNIFICANT SECTION OF THE COMMUNITY AND WHICH ARE NOT PERMITTED BY THEIR CONSTITUTION TO MAKE A PROFIT FOR PRIVATE DISTRIBUTION. VOLUNTARY ORGANISATIONS DO NOT INCLUDE LOCAL GOVERNMENT OR OTHER STATUTORY AUTHORITIES

Activities: The Association is a membership association for members of the medical profession working with patients with cancer. It corresponds with its membership regularly to give them updates and information. It also runs a Scientific Conference annually, which features guest lectures, symposia and submitted abstracts. A more extensive programme of meetings is being developed.

Classification

- **How:** Makes Grants To Individuals, Makes Grants To Organisations, Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research, Acts As An Umbrella Or Resource Body
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** The General Public/mankind

Geography

- **Area of benefit:** UNDEFINED. IN PRACTICE, NATIONAL.
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-06-30	£214,654	£247,495	-	-
2024-06-30	£218,053	£221,021	-	-
2023-06-30	£120,299	£146,434	-	-
2022-06-30	£133,080	£111,143	-	-
2021-06-30	£138,739	£79,565	-	-

Trustees

Name	Role	Appointed
Abigail Tomlins		2023-11-06
Anant Desai		2020-11-23
Avi Agrawal		2021-11-21
David Holroyd		2025-11-10
Melissa Cunha		2023-11-06
Mr Ibrahim Sallam		2024-11-04
Ms Gloria Petralia		2024-11-04
Pankaj Roy Gupta		2023-11-06
Paul Skaife		2021-11-21
Professor Anastasios Kanatas		2024-11-04
Professor Jayant Vaidya		2019-11-17

Accounts

COMPANY REGISTRATION NUMBER : 7225131

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
UNAUDITED FINANCIAL STATEMENTS
FOR
YEAR ENDED 30 JUNE 2025**

Charity Number : 1136067



Edmund Carr LLP
Chartered Accountants
146 New London Road
Chelmsford
Essex
CM2 OAW

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2025**

CONTENTS	PAGE
Company information	1
Trustees' annual report	2
Independent Examiner's report to the Trustees	12
Statement of financial activities	13
Balance sheet	14
Notes to the financial statements	15

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
COMPANY INFORMATION**

YEAR ENDED 30 JUNE 2025

Charity Number	1136067
Company Number	7225131
Registered Office	38-43 Lincoln's Inn Fields London WC2A 3PE

THE TRUSTEES

The Trustees of the charity are also the directors of the charity.

The Trustees who served the charity during the year were as follows:

Professor Michael Douek	President	
Professor Jayant Vaidya	Vice President	
Professor Anant Desai	Honorary Secretary	
Mr Michael Shackcloth	Honorary Treasurer	(Demitted 4/11/2024)
Miss Abigail Tomlins	Honorary Treasurer	(Appointed 4/11/2024)
Mr John Whiting	EJSO Representative	(Demitted 4/11/2024)
Professor PG Roy	EJSO Representative	(Appointed 4/11/2024)
Professor Jim Khan	Meeting Secretary	
Mr Avi Agrawal		
Miss Melissa Cunha	Deputy Meeting Secretary	
Mr Aaron Quyn		
Mr Paul Skaife		
Professor Anastasios Kanatas	(Appointed 4/11/2024)	
Ms Gloria Petralia	(Appointed 4/11/2024)	
Mr Ibrahim Sallam	(Appointed 4/11/2024)	

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT
YEAR ENDED 30 JUNE 2025**

The Trustees have pleasure in presenting their report and the unaudited financial statements for the charity for the year ended 30th June 2025. The Trustees of the charity as shown above are also the directors of the charity.

OBJECTIVES AND ACTIVITIES

The Charity's objectives are:

To advance the science, practice, and art of surgical oncology for the benefit of patients with cancer; and **to promote research, training, and education in surgical oncology** for the benefit of the public, patients and the medical community, and to disseminate the useful results of that research appropriately.

The Association serves as an umbrella organisation for professionals across all surgical cancer specialties and cancer research. Additionally, the Society is dedicated to driving innovation in cancer care, supporting the training and development of the future workforce, and ensuring our activities align with the Charity Commission's guidance on public benefit.

Portfolio of BASO Prizes and Awards

The Association is proud to offer a variety of awards aimed at inspiring our junior colleagues and fostering their passion for surgical oncology, cancer research, and patient care. For more details, visit: <https://baso.org.uk/education-training.aspx>. At our annual scientific meeting, the Society continues to present the following prestigious prizes:

- **Alan Edwards Memorial Prize** is awarded to the best poster presentation.
- **Ronald Raven Presentation Prize** is awarded to the best oral paper presentation.
- **BASO~ACS Presentation Prize**, formerly known as BJS Prize, is awarded to the best oral paper presentation. As a result of a structural change, the British Journal of Surgery Society (BJSS) ceased its support for this prize. In 2019, BASO Council unanimously decided to sponsor this prize to ensure continued existence to the BJS Paper Presentation Prize awarded at the BASO Meeting.
- **BASO Trainees (poster/oral presentation) Prize** is awarded to the best poster and oral paper presentations at the BASO Trainees Meeting.

To expand its commitment to all cancer-related professionals, BASO also presents the following prizes:

- **BASO Trainees Audit/QIP Prize** to support and encourage trainees, those involved with audit and quality improvement with a view of improving care to patients, in particular, cancer patients.
- **BASO Multidisciplinary Prize** to recognise the work done by our Non-Medical Professional colleagues in supporting cancer patients. This unique award is designed to highlight any research, audit, quality improvement, health service provision/development, cancer patient pathway study, cancer survivorship study.
- **BASO Medical Student Prize** to support and encourage medical students with an interest in surgical oncology.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)**

YEAR ENDED 30 JUNE 2025

Additionally, BASO annually offers a range of prizes to encourage and promote trainees' enthusiasm for surgical oncology. These awards are presented to the trainee who delivers the best surgical oncology presentation at various surgical specialty associations' annual scientific conferences.

BASO has established a prestigious collection of awards, recognising surgeons for their outstanding achievements and contributions to cancer surgery, research, and education.

In addition to the **Ronald Raven Lifetime Achievement Award** (introduced in 2013), the **Geoff Oates Award** (2014), and the **Uccio Querci della Rovere Award** (2014), BASO introduced the **BASO Medal for Excellence** in 2022 to mark the 50th anniversary of the Association's founding. This prestigious honour recognises outstanding contributions by individual surgeons or teams in advancing cancer care through excellence in **research, clinical practice, education, and innovation**.

The **BASO Medal for Excellence** is an international accolade presented every five years, with nominations open to both members and non-members. It recognises outstanding contributions to the advancement of cancer surgery in the UK. BASO was proud to award the **inaugural medal to Professor Freddie Hamdy** in July 2022.

For more details, follow the link: <https://baso.org.uk/baso~acs-conferences/baso-50thanniversary-meeting.aspx>.

BASO~ACS Research Grants

BASO continues to expand its portfolio of research grants to support innovative cancer research. For more information, visit: <https://baso.org.uk/education-training.aspx>

Ronald Raven Travelling Fellowship

Established in 1993 by the Ronald Raven Trustees in memory of Ronald W. Raven, the founder of the Association, this fellowship is awarded annually. BASO continues to fund this **£3,000 fellowship**, supporting aspiring trainees in developing their skills and experience in surgical cancer treatment.

BASO (NIHR) Research Project Grant

As a non-commercial partner with the National Institute for Health Research (NIHR), BASO successfully ran a research project grant scheme to assist surgeons undertaking cancer-related research. Awarded projects were eligible for Clinical Research Network Support and inclusion in the NIHR portfolio.

In 2021, BASO launched a new **Research Grant in Cancer Surgery** in collaboration with the **Rosetrees Trust**, which replaced the BASO (NIHR) Research Project Grants in 2022.

BASO/Rosetrees Research Grants in Cancer Surgery

To celebrate BASO's 50th Anniversary, the National Committee introduced a new three-year research grant partnership with the Rosetrees Trust. This collaboration provides **annual grants of up to £50,000**, with matching funds from the Rosetrees Trust.

The first round of grants was awarded at BASO's 50th Anniversary Celebration Meeting. Successful applications may be considered for inclusion in the **NIHR portfolio** and are encouraged to seek support from the **Royal College of Surgeons of England's Surgical Interventional Trials Unit (SITU)**.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)
YEAR ENDED 30 JUNE 2025**

Endorsement of Regional Events

The Association strives to engage with oncologists and related societies at the regional level. Through its network of Regional Representatives, BASO has actively supported a variety of regional and national meetings throughout this accounting year.

Engagement with Medical Students

In its commitment to nurturing the next generation of surgical oncologists, the Association has opened its Trainee membership to Foundation Year Trainees and Medical Students aspiring to pursue a career in surgical oncology. BASO provides valuable support for their surgical career development through skills courses, mentoring sessions, and portfolio guidance, leveraging its extensive network of regional representatives.

The Society also actively engages with undergraduate Medical Societies by sponsoring annual meetings with the BASO Prize and hosting sponsored lectures.

BASO Trainees Group

The BASO Trainees group has consistently broadened its reach and strengthened ties with trainee groups across the UK and Europe. These collaborations have allowed us to inspire trainees in the principles of research and clinical excellence in surgical oncology, through the sponsorship of prizes and lectures at national specialty meetings. Our Trainees group remains committed to advancing research, academic training, education and fellowship opportunities.

BASO's contribution to NICE consultations

The Society continues to make a significant impact by providing expert advice on numerous site-specific surgical cancer consultations and guidelines, as requested by NICE. Our Council members actively contribute to various Cancer Clinical Reference Groups (CRGs), offering their specialised expertise.

Additionally, the Society maintains strong relationships with surgical societies and the Royal Colleges, while continuously seeking new opportunities for collaboration.

ACHIEVEMENTS AND PERFORMANCE

The Society remains firmly committed to supporting the training and educational development of its members and colleagues. It continues to demonstrate the value of a unified umbrella organisation by **actively growing its membership, fostering research collaborations through grant funding, and supporting a wide range of educational events**. Backed by **sound financial stability**, the Society is well positioned to **deliver high-quality educational meetings and initiatives that advance cancer surgery and cancer research**.

BASO Annual Scientific Meeting

BASO 2024 delivered an exceptional programme, featuring a distinguished lineup of national and international experts in cancer surgery. Themed **“Surgical Excellence in Cancer Care,”** the meeting was led by BASO President Professor Michael Douek, Meeting Secretary Professor Jim Khan, and Deputy Meeting Secretary Miss Melissa Cunha, and offered a rich mix of educational and thought-provoking sessions across all aspects of surgical oncology.

The conference featured plenary sessions, keynote lectures, and roundtable discussions spanning a wide range of disciplines, fostering collaboration, networking, and the exchange of ideas among professionals.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)
YEAR ENDED 30 JUNE 2025**

To **enhance member benefits and encourage participation**, registration fees were **subsidised for BASO and Trainee members**, improving accessibility for our valued community.

The meeting focused on best practices in surgical oncology, delivering valuable insights into surgical cancer research and management across various specialties. It provided excellent learning opportunities for both experienced consultants and trainees—whether pursuing a career in surgical oncology or exploring other surgical disciplines. Delegate feedback was overwhelmingly positive.

Approximately 100 abstracts were submitted, with eight abstract prizes awarded for outstanding presentations. The programme also included several prestigious eponymous lifetime achievement awards and orations, honouring some of the leading surgeons of our time.

BASO remains committed to building on the success of this programme while ensuring the financial sustainability of future BASO meetings.

European Journal of Surgical Oncology

The **EJSO**, co-owned by BASO and ESSO, continues to thrive with improved submission quality and increased article downloads. The 2024 impact factor, released in June, has risen to 4.424 (for more details, visit: https://journalinsights.elsevier.com/journals/0748-7983/impact_factor_5_year). This significant increase in citations is a testament to the outstanding work of the editorial team, led by our past President, Professor Riccardo Audisio (Editor-in-Chief).

Network and links with other organisations

The Association is actively building and strengthening links with other specialties, fostering collaboration through membership partnerships, advisory input, mentoring opportunities, and plans for future joint conferences.

To further encourage collaboration and engagement, BASO Trainees is actively working with various trainees groups as well medical student societies to inspire and support medical students interested in careers in surgical oncology.

European Society of Surgical Oncology

BASO maintains a strong partnership with its European sister society, **ESSO**. Under their Memorandum of Understanding, BASO members enjoy full ESSO membership privileges, including reduced registration for conferences and courses, access to career development programs, members-only website content, and voting rights at the ESSO General Assembly.

National Clinical Guidelines

BASO plays a key role in developing and updating National Clinical Guidelines. Council members serve as Specialist Advisors for NICE's Interventional Procedure Programmes, while BASO Trustees actively contribute to consultations and participate in multiple Cancer Commissioning Groups.

All-Party Parliamentary Group on Cancer

BASO is a stakeholder in the All-Party Parliamentary Group on Cancer. As the sole organisation representing the surgical community, BASO is uniquely positioned to engage policymakers and advocate for the interests of oncology surgeons.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)**

YEAR ENDED 30 JUNE 2025

Cancer Services Committee

BASO has chaired the Royal College of Surgeons of England's Cancer Services Committee (CSC) over 20 years, which united representatives from all surgical societies, Royal Colleges, patient liaison groups, and Macmillan to present a unified surgical voice on cancer care.

Paused in May 2022 to review its remit and structure, the CSC was reinstated following BASO's discussions with the College and continued to play a key role in shaping cancer service policy and commissioning.

In January 2025, the RCS announced a restructure of all its committees, including the CSC. The restructured CSC would sit under the Workforce and Planning Group, to be chaired and co-chaired by RCS Council members, with full administrative support from the College. BASO awaits further updates on this transition.

National Committee for Cancer Surgery

The BASO~ACS Council is proud to announce the establishment of a new and independent **National Committee on Cancer Surgery (NCCS)**, which aspires to be the *one unified voice* for cancer surgery in the UK. The NCCS serves as a critical and independent authority on policy and strategy (including infrastructure), answerable solely to patients and cancer surgeons. Its primary remit is to drive the delivery of the highest quality cancer treatment, alongside providing strategic advice on research and development, and fostering engagement with international and global cancer surgery communities.

To ensure it truly represents the voice of cancer surgery, the NCCS includes representation from all major surgical societies, the four Royal Colleges of Surgeons, the Royal College of Pathologists, the Royal College of Radiologists, and the Royal College of Obstetricians and Gynaecologists. The committee provides independent, expert advice to the NHS, the Department of Health (DoH), and the All-Party Parliamentary Group for Cancer (APPGC). It also produces and publishes policy documents and works to disseminate these widely through leading medical journals, the public, press, and policymakers.

In 2025, the NCCS successfully convened three committees and has set ambitious plans to continue and expand its work into 2026.

BASO/Rosetrees Research Grants in Cancer Surgery

In recognition of the success of this partnership, the **Rosetrees Trust** has agreed to **extend the collaboration for a further five years under the same funding arrangement**, allowing BASO~ACS to continue awarding these research grants. BASO Council is thankful to the Rosetrees Trust for their support in reaching this milestone.

Sponsorship Platform for Clinical Trials

BASO Council has developed a sponsorship platform and has secured the necessary contractual, legal, and insurance expertise to enable BASO~ACS to sponsor clinical trials that are considered important and worthy of support by the Society. This function is currently managed by NHS Trusts or universities.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)
YEAR ENDED 30 JUNE 2025**

Covid Inquiry Submission

BASO~ACS submitted a witness statement to the **COVID-19 Inquiry**, presenting the Society's perspective on events during the pandemic. The statement was prepared in the format requested by the Inquiry team, and BASO has been informed that **no in-person attendance will be required**.

Medical Student Elective Award

BASO Council has approved the establishment of a bursary to support medical students undertaking an elective in surgical oncology. The award will provide up to £2,000 to one or two successful applicants. The call for applications will be announced shortly, offering travel support for medical students during their surgical oncology electives over the coming year.

BASO Endorsed Meetings

This year, BASO endorsed the following events and meetings:

- International Masterclass in Hepatobiliary Surgery – September 2023
- Effective Tumour Board Setup and Multidisciplinary Decision making For Cancer Patients – December 2024
- 9th Portsmouth Colorectal Congress – June 2025
- BASO @BGCS Annual Conference - July 2025

BASO~ACS remains committed to advancing cancer treatment, research, patient care, and the education and training of the next generation of oncologists.

FINANCIAL REVIEW

Membership

Membership numbers have remained steady over the past year. The Society recognises the importance of growing its membership base and will be placing renewed emphasis on targeted recruitment and engagement initiatives in the coming year.

To support this objective and to encourage new members to join, the **membership fees will remain unchanged for this accounting period**. This approach aims to maintain accessibility while the Society works to expand its reach and strengthen its professional community.

As agreed at the 2017 AGM, BASO offers a 50% discount on Full Membership for a period of two years to BASO Trainees members who have completed their training. This benefit is available to those who have maintained continuous membership for two consecutive years as paying members.

EJSO

Profits generated from the *EJSO* continue to play an important role in supporting the Society. These profits are used to offset the cost of membership subscriptions to the journal and are reflected in the Society's final financial reconciliation.

In **2024**, the journal delivered a **healthy profit of £113,512** to BASO~ACS, after deducting the Society's membership subscription costs for the year. This strong financial performance highlights the journal's ongoing value as both a scientific resource and a revenue stream.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)**

YEAR ENDED 30 JUNE 2025

Revenue from **electronic institutional subscriptions**—primarily through e-only licences and bundled collections—has continued to show **steady growth**, reflecting the wider shift toward digital access. Conversely, and as expected, **print subscription revenues have declined** as more institutions and individuals transition to online formats.

There has also been a **notable increase in the number of authors choosing to publish Open Access**. This trend has generated **substantial growth in Open Access revenue**, supported by the journal's global reach and impact. BASO members continue to benefit from a **30% discount on Open Access publication fees**, which supports and encourages member-led research dissemination.

Looking ahead, it is anticipated that the *EJSO* will continue its positive trajectory and expand its impact under the **editorship of Professor Riccardo A. Audisio**.

BASO Grants and Prizes

1. **BASO/Rosetrees Research Grants in Cancer Surgery** 2024 is awarded to:

Mr George Adigbli - *Lymph Liquid Biopsy for Early Melanoma Risk Stratification: A Proof-of-Concept Study*

Dr Jack Helliwell - *Determining the role of the microbiome in the development of anaStomotiC leak after rectal cancer surgery: a prOspective obseRvational study (DISCOVERY)*

Miss Mhairi Mactier - *Exploring the association between post-operative complications and oncological outcomes in breast cancer surgery*

2. **Ronald Raven Travelling Fellowship Grant** 2024 is awarded to **Ms Andrea Sheel**, HPB and General Surgeon, University of Liverpool NHS FT.

3. **BASO Trainees Prize** were awarded at the following external meetings:

SCTS Annual Scientific Meeting

ASiT Annual Conference

BASO Trainees Research Forum

BASO Annual Meeting 2024

The BASO Trustees remain confident that the Charity is successfully fulfilling its objectives by promoting and supporting advancements in surgical oncology research and education. This commitment was clearly reflected in the success of the **2024 Annual Scientific Meeting**.

While the event incurred a **planned loss** due to the higher logistical costs of hosting in London, this outcome had been anticipated and strategically approved by the National Committee. The decision to offer **subsidised registration for junior members** was made to support early-career professionals and encourage greater engagement with the Society. The Committee agreed that delivering a high-quality, well-attended meeting was essential to advancing BASO's charitable aims and would also contribute to **long-term membership growth**.

The conference significantly **enhanced the Association's profile within the cancer research community**, strengthened collaborations with partner organisations, and provided an **outstanding networking platform** for BASO members. These efforts have already resulted in the **recruitment of new members** and increased visibility of the Society's work.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)**

YEAR ENDED 30 JUNE 2025

BASO continues to maintain **strong financial reserves** and has secured a **sustainable income stream from the EJSO**, which will support ongoing investment in education, training, and research through future Annual Conferences. Looking ahead, the Trustees are committed to **transitioning towards a cost-neutral conference model**, while maintaining the high standards and impact of BASO events.

Reserves Policy

BASO~ACS maintains a prudent level of reserves to ensure the Association can meet its financial obligations in the event of a shortfall from the annual conference, while also supporting low delegate fees and avoiding increases to Membership fees. The level of reserves, together with income from conferences and subscriptions, remains central to achieving the Association's objectives.

The Trustees carefully monitor reserves to maintain an appropriate balance between safeguarding financial stability and keeping costs for Members and prospective Members as low as possible. They consider it prudent to hold free reserves in the region of £125,000 to cover the costs of the annual scientific conference, annual administration, and commitments made towards BASO/Rosetrees Research grants.

As at 31 March 2025, free reserves stood at £218,595, exceeding the target threshold. This strong position enables BASO~ACS to continue its policy of maintaining low subscription fees, subsidising conference registration fees for delegates, supporting further research grants. The reserve also provide a safeguard against any unforeseen operational costs of the BASO Office.

Investment Policy

The Trustees have power under the Articles to invest funds in the same manner and subject to the same conditions as the Trustees of a trust are permitted to do by the Trustee Act 2000. The Association currently holds its reserves across three deposit accounts: BASO ~ ACS holds reserves in a Scottish Widows 90-day notice account; an instant access account with Lloyds TSB; and a further instant access account with Virgin Money. BASO Trustees are looking into new investment opportunities for the Association's reserves.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Structure

On 1st July 2010, a formal transfer was made from the unincorporated charity, *BASO ~ The Association for Cancer Surgery*, to a newly incorporated company limited by guarantee of the same name (Company No. 7225131, Registered Charity No. 1136067). The company had been incorporated on 15 April 2010, when new Articles of Association were established.

At the same time, corresponding transfers were made to the newly formed Association of Breast Surgery (ABS), also a company limited by guarantee (Company No. 7207053, Registered Charity No. 1135699). From that point, the two Associations became legally independent entities, while entering into a service agreement to support any shared administrative functions.

Over time, the degree of operational separation has increased to allow each Association to develop its own identity and strategic direction, while maintaining a collaborative relationship on matters of shared interest.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)**

YEAR ENDED 30 JUNE 2025

In May 2020, both Associations completed the separation of their joint database and IT systems, while agreeing to retain historical records of joint members and records of cross-attendance (ABS members attending BASO events and vice versa). The service agreement remains in place and is periodically reviewed to ensure its continued relevance and fairness to both parties.

At present, no further significant structural changes are anticipated, and both Associations continue to work cooperatively while pursuing their individual missions.

Governance and Management

Ordinary Members of the BASO~ACS Council and the Honorary Officer position of Vice President (all of whom also serve as Trustees and Directors) are elected through a ballot of the Association's Membership, following a formal call for nominations.

Officer posts are similarly announced through a call for nominations. If more than one nomination is received for a post (excluding the Vice President role), a ballot is held among the Trustees.

All Honorary Officers also serve as Trustees and Directors. All appointments are subsequently ratified by the Membership at the AGM.

The BASO~ACS Council holds National Committee meetings four times a year, where the key business of the Association is considered and agreed. Between meetings, decisions are made via telephone or email communication between the Honorary Officers, while day-to-day operational matters are managed by the Association Manager in consultation with the Honorary Officers.

The Trustees/Directors regularly review the principal risks facing the charity and its reserves policy. This process is supported by an annual internal audit of controls over key financial systems, ensuring the charity maintains sufficient resources to respond to adverse conditions. No major risks were identified by the Trustees during the year.

In determining the activities of the charity, the Trustees have regard to the Charity Commission's guidance on public benefit.

PLANS FOR THE FUTURE

Expanding the core membership and increasing the range of specialisms represented remain key objectives for 2024–25. While overall growth in membership has been steady rather than increasing, numbers have remained stable, reflecting strong engagement and retention. The Trustees are actively strengthening relationships with other Associations, fostering improved communication and collaboration in areas of shared interest. The current Trustees themselves represent a wide array of specialisms, bringing valuable experience and diverse perspectives to the Association's governance.

Plans are underway to support smaller, complex cancer surgical groups by offering BASO affiliation and endorsement of their meetings. This initiative will further establish BASO as the umbrella Society for all cancer surgeons, enhancing its role and influence across the specialty.

BASO continues to make significant contributions to national consultations, including those organized by NICE. Trustees are actively building collaborations with Royal Colleges, Cancer Commissioning Boards, Public Health England, the GMC, and other stakeholders, with the aim of sharing knowledge, stimulating debate, and promoting best practice to improve outcomes for cancer patients.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)**

YEAR ENDED 30 JUNE 2025

Research remains a key focus, with BASO funding research grants in partnership with the Rosetrees Trust to support surgical oncology studies. This initiative broadens the scope of research in surgical oncology, with shortlisted projects eligible for inclusion in the NIHR portfolio.

BASO also continues to sponsor and support regional meetings and Student Surgical Societies, fostering engagement and professional development across all levels of surgical education. Trainee membership has been extended to Medical Students and Foundation Year Trainees with an interest in surgical oncology, providing structured support for education, training, and career progression.

As healthcare evolves and training pressures increase, BASO Trainees are focused on enhancing the training experience and professional competence of surgical trainees in oncology, particularly within academic and research domains.

This report has been prepared having taken advantage of the small companies exemption in the Companies Act 2006.

Approved by the Trustees on 10 Nov. 2025 and signed on their behalf by:

Abigail Tomlins

**Miss Abigail Tomlins
Honorary Treasurer**

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES
YEAR ENDED 30 JUNE 2025**

I report to the charity trustees on my examination of the accounts of the company for the year ended 30 June 2025 which are set out on pages 13 to 20.

Responsibilities and basis of report

As the charity trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Alex Stone

.....
Alex Stone FCCA

Edmund Carr LLP
146 New London Road
Chelmsford
CM2 0AW

19 January 2026
.....

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

**STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND
EXPENDITURE ACCOUNT)**

YEAR ENDED 30 JUNE 2025

		Unrestricted Funds	Restricted Funds	Total Funds 2025	Total Funds 2024
	Note	£	£	£	£
INCOME from:					
Donations - Rosetrees Trust		-	25,000	25,000	25,000
Charitable activities:					
Members' subscriptions		33,765	-	33,765	34,726
BASO Conference and Meetings	2	27,508	-	27,508	33,780
Publications - EJSO		124,747	-	124,747	120,040
Investments	3	2,102	1,532	3,634	4,507
TOTAL INCOME		<u>188,122</u>	<u>26,532</u>	<u>214,654</u>	<u>218,053</u>
EXPENDITURE on:					
Charitable activities					
Subscriptions - ESSO		9,295	-	9,295	9,773
BASO Conference and Meetings	2	59,995	-	59,995	51,038
Publications - EJSO		11,235	-	11,235	9,828
Fellowships & awards	4	28,583	29,000	57,583	50,918
Other expenditure	5	109,387	-	109,387	99,464
TOTAL EXPENDITURE		<u>218,495</u>	<u>29,000</u>	<u>247,495</u>	<u>221,021</u>
NET INCOME/(EXPENDITURE)		(30,373)	(2,468)	(32,841)	(2,968)
Transfers between funds		-	-	-	-
NET MOVEMENT IN FUNDS		(30,373)	(2,468)	(32,841)	(2,968)
RECONCILIATION OF FUNDS					
Total funds brought forward		249,186	28,604	277,790	280,758
Total funds carried forward		<u>218,813</u>	<u>26,136</u>	<u>244,949</u>	<u>277,790</u>

The charity has no recognised gains or losses other than the results for the period as set out above.

The notes on pages 15 to 20 form part of these financial statements.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
BALANCE SHEET
AS AT 30 JUNE 2025**

		2025		2024	
	Note	£	£	£	£
FIXED ASSETS					
Tangible assets	10		218		292
CURRENT ASSETS					
Debtors	11	45,722		43,986	
Cash at bank		318,080		335,855	
		<u>363,802</u>		<u>379,841</u>	
CREDITORS: Amounts falling due within one year	12	<u>(119,071)</u>		<u>(102,343)</u>	
NET CURRENT ASSETS			244,731		277,498
TOTAL ASSETS LESS CURRENT LIABILITIES/ NET ASSETS			<u>244,949</u>		<u>277,790</u>
FUNDS					
Unrestricted	13		218,813		249,186
Restricted	14		26,136		28,604
TOTAL FUNDS			<u>244,949</u>		<u>277,790</u>

For the year ending 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006 and with the Financial Reporting Standard (FRS102) (effective 1 January 2019).

These financial statements were approved by the Trustees on...10 Nov 2025... and are signed on their behalf by:

Michael Douek

PROFESSOR MICHAEL DOUEK

Abigail Tomlins

MISS ABIGAIL TOMLINS

Company Registration Number: 7225131

The notes on pages 15 to 20 form part of these financial statements.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2025

1. ACCOUNTING POLICIES

Basis of accounting

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

BASO - The Association for Cancer Surgery meets the definition of a public benefit entity under FRS102. Assets and Liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes. The financial statements are prepared in sterling, which is the functional currency of the charity, and rounded to the nearest £. The charity is a company limited by guarantee.

Going Concern

The financial statements have been prepared on a going concern basis as the Trustees believe that no material uncertainties exist. The Trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern.

Incoming Resources

Income from conferences held during the year is accounted for on an accruals basis. Membership subscriptions are recognised on receipt.

Resources Expended

All expenditure is accounted for on an accruals basis and includes VAT as the charity is not VAT registered. The majority of costs are attributable to specific charitable activities (ie conferences/awards). Fellowships and awards are accounted for in the period in which they are notified to the recipient. Governance costs are associated with the governance arrangements of the charity.

Debtors and creditors

Trade and other debtors are recognised at the settlement amount due. Creditors are recognised at their settlement amount.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and deposits.

Fixed Assets and Depreciation

Fixed assets are shown at historical cost. Expenditure on tangible fixed assets is capitalised. The cost of other items is written off as incurred.

Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:

Computer equipment	25% reducing balance
Fixtures & fittings	25% reducing balance

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2025**

ACCOUNTING POLICIES continued

Fund accounting

Funds held by the charity are either:

Unrestricted general funds – these are funds which can be used in accordance with the charitable objects at the discretion of the trustees.

Restricted funds – these are funds that can only be used for particular restricted purposes within the objects of the charity.

2. CHARITABLE ACTIVITIES

SCIENTIFIC CONFERENCE AND MEETINGS

	Unrestricted Funds	Restricted Funds	Total Funds 2025	Total Funds 2024
	£	£	£	£
Income				
BASO Conference Fees	22,428	-	22,428	31,780
Lecture grants	4,500	-	4,500	2,000
Other meetings	580	-	580	-
	<u>27,508</u>	<u>-</u>	<u>27,508</u>	<u>33,780</u>
Expenditure				
BASO Conference	59,972	-	59,972	50,899
Other meetings	23	-	23	139
	<u>59,995</u>	<u>-</u>	<u>59,995</u>	<u>51,038</u>

3. INVESTMENT INCOME

All of the charity's investment income arises from interest bearing deposit accounts.

4. FELLOWSHIPS & AWARDS

	Unrestricted Funds	Restricted Funds	Total Funds 2025	Total Funds 2024
	£	£	£	£
Ronald Raven Prize	-	600	600	600
Ronald Raven Travel Scholarships	-	3,000	3,000	-
Alan Edwards Memorial Fund	-	400	400	400
BASO/Rosetrees Research Grant	25,000	25,000	50,000	50,000
Other awards and medals	3,583	-	3,583	1,418
Unclaimed awards released	-	-	-	(1,500)
	<u>28,583</u>	<u>29,000</u>	<u>57,583</u>	<u>50,918</u>
2024	26,418	24,500	50,918	

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2025

5. OTHER EXPENDITURE

	Unrestricted Funds	Restricted Funds	Total Funds 2025	Total Funds 2024
	£	£	£	£
Clinical trial sponsorship platform	5,757	-	5,757	-
Staff salaries and pension costs	63,106	-	63,106	55,390
National committee costs	6,092	-	6,092	12,784
Website and IT costs	16,523	-	16,523	10,988
Rent, insurance and sundry expenses	11,016	-	11,016	8,054
Governance costs (note 6)	6,893	-	6,893	12,248
	<u>109,387</u>	<u>-</u>	<u>109,387</u>	<u>99,464</u>
<i>2024</i>	<i>99,464</i>	<i>-</i>	<i>99,464</i>	

6. GOVERNANCE COSTS

	Unrestricted Funds	Restricted Funds	Total Funds 2025	Total Funds 2024
	£	£	£	£
Accounting and payroll services	4,503	-	4,503	4,441
Independent examination fee	675	-	675	650
Fees payable to independent examiner	5,178	-	5,178	5,091
Bank charges	549	-	549	510
Legal and professional fees	1,166	-	1,166	6,647
	<u>6,893</u>	<u>-</u>	<u>6,893</u>	<u>12,248</u>

7. STAFF COSTS AND EMOLUMENTS

Total staff costs were as follows:

	2025	2024
	£	£
Wages & salaries	58,371	49,500
Pension costs (defined contribution scheme)	4,735	5,890
	<u>63,106</u>	<u>55,390</u>

Particulars of employees:

The average number of employees during the year was 1, (full-time equivalent - 0.8)
(2024 - 1 employee and 0.8 FTE)

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2025**

8. NET OUTGOING RESOURCES FOR THE YEAR

	2025	2024
	£	£
This is stated after charging:		
Depreciation	74	177

9. TRUSTEES' REMUNERATION

None of the Trustees were paid any remuneration by the Association during the period.
Trustees are reimbursed reasonable expenses incurred when acting on behalf of the company.
Expenses totalling £1,225 were reimbursed to 8 trustees during the period
(2024 - £4,895 to 11 Trustees).

10. TANGIBLE FIXED ASSETS

	Computer equipment £	Fixtures & fittings £	Total £
COST			
At 1 July 2024	2,691	611	3,302
Additions	-	-	-
Disposals	-	-	-
At 30 June 2025	2,691	611	3,302
DEPRECIATION			
At 1 July 2024	2,399	611	3,010
Charge for the year	74	-	74
Disposals	-	-	-
At 30 June 2025	2,473	611	3,084
NET BOOK VALUE			
At 30 June 2025	218	-	218
At 30 June 2024	292	-	292

11. DEBTORS

	2025	2024
	£	£
Trade debtors	-	410
Prepayments and accrued income	26,986	24,656
Other Debtors	18,736	18,920
	45,722	43,986

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS**

YEAR ENDED 30 JUNE 2025

12. CREDITORS: Amounts falling due within one year

	2025	2024
	£	£
Trade creditors	12,878	2,301
Grants payable	38,621	30,000
Accruals	7,624	8,650
Deferred income	59,948	61,392
	<u>119,071</u>	<u>102,343</u>

Deferred income relates to EJSO royalties received in advance for the following period.

13. UNRESTRICTED FUNDS

Current year	Movement in resources:				Balance at 30/06/2025 £
	Balance at 01/07/2024 £	Incoming £	Outgoing £	Transfers £	
General unrestricted funds	<u>249,186</u>	<u>188,122</u>	<u>(218,495)</u>	<u>-</u>	<u>218,813</u>
<i>Prior year</i>	<i>Balance at 01/07/2022 £</i>	<i>Incoming £</i>	<i>Outgoing £</i>	<i>Transfers £</i>	<i>Balance at 30/06/2024 £</i>
<i>General unrestricted funds</i>	<u>254,485</u>	<u>191,222</u>	<u>(196,521)</u>	<u>-</u>	<u>249,186</u>

14. RESTRICTED FUNDS

Current year	Movement in resources:				Balance at 30/06/2025 £
	Balance at 01/07/2024 £	Incoming £	Outgoing £	Transfers £	
a) Alan Edwards Memorial Fund	4,904	265	(400)	-	4,769
b) Ronald Raven Prize Fund	1,237	188	(600)	-	825
c) Ronald Raven Travelling Fund	22,463	1,079	(3,000)	-	20,542
d) BASO/Rosetrees Fund	-	25,000	(25,000)	-	-
	<u>28,604</u>	<u>26,532</u>	<u>(29,000)</u>	<u>-</u>	<u>26,136</u>

a)-c) Prize funds awarded annually

d) Donations from the Rosetrees Trust towards the joint BASO/Rosetrees Research grants.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2025**

14. RESTRICTED FUNDS

<i>Prior year</i>	<i>Movement in resources:</i>				<i>Balance at 30/06/2024</i>
	<i>Balance at 01/07/2023</i>	<i>Incoming</i>	<i>Outgoing</i>	<i>Transfers</i>	
	£	£	£	£	£
a) <i>Alan Edwards Memorial Fund</i>	4,931	373	(400)	-	4,904
b) <i>Ronald Raven Prize Fund</i>	1,567	270	(600)	-	1,237
c) <i>Ronald Raven Travelling Fund</i>	19,775	1,188	1,500	-	22,463
d) <i>BASO/Rosetrees Fund</i>	-	25,000	(25,000)	-	-
	<u>26,273</u>	<u>26,831</u>	<u>(24,500)</u>	<u>-</u>	<u>28,604</u>

15. ANALYSIS OF NET ASSETS (between restricted and unrestricted funds)

<i>Current year</i>	<i>Tangible fixed assets</i>	<i>Other net assets</i>	<i>Total</i>
	£	£	£
Restricted funds	-	26,136	26,136
Unrestricted funds	218	218,595	218,813
	<u>218</u>	<u>244,731</u>	<u>244,949</u>
<i>Prior year</i>	<i>Tangible fixed assets</i>	<i>Other net assets</i>	<i>Total</i>
	£	£	£
<i>Restricted funds</i>	-	28,604	28,604
<i>Unrestricted funds</i>	292	248,894	249,186
	<u>292</u>	<u>277,498</u>	<u>277,790</u>

16. COMPANY LIMITED BY GUARANTEE

The company is controlled by its members. Every member of the company undertakes to contribute to the assets of the Company in the event of the same being wound up during the time he/she is a member, or within one year afterwards, for the payments of the debts and liabilities of the company contracted before the time at which he/she ceases to be a member and of the costs, charges and expenses of winding up the same, and for the adjustments of the rights of the contributors among themselves such amount as may be required not exceeding one pound.

17. RELATED PARTY TRANSACTIONS

There were no related party transactions that require disclosure during the year other than the reimbursement of expenses to Trustees, disclosed in Note 9.

Accounts

COMPANY REGISTRATION NUMBER : 7225131

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
UNAUDITED FINANCIAL STATEMENTS
FOR
YEAR ENDED 30 JUNE 2024**

Charity Number : 1136067



Edmund Carr LLP
Chartered Accountants
146 New London Road
Chelmsford
Essex
CM2 OAW

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2024**

CONTENTS	PAGE
Company information	1
Trustees' annual report	2
Independent Examiner's report to the Trustees	12
Statement of financial activities	13
Balance sheet	14
Notes to the financial statements	15

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
COMPANY INFORMATION**

YEAR ENDED 30 JUNE 2024

Charity Number	1136067
Company Number	7225131
Registered Office	38-43 Lincoln's Inn Fields London WC2A 3PE

THE TRUSTEES

The Trustees of the charity are also the directors of the charity.

The Trustees who served the charity during the year were as follows:

Professor Michael Douek	President
Mr Zaed Hamady	(Demitted 6/11/2023)
Professor Jayant Vaidya	Vice President
Professor Anant Desai	Honorary Secretary
Mr Michael Shackcloth	Honorary Treasurer
Mr John Whiting	EJSO Representative
Professor Jim Khan	Meeting Secretary
Mr Avi Agrawal	
Miss Melissa Cunha	(Appointed 6/11/2023)
Professor Derek Manas	(Demitted 6/11/2023)
Mr Aaron Quyn	
Professor PG Roy	(Appointed 6/11/2023)
Mr Paul Skaife	
Mrs Abigail Tomlins	

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT
YEAR ENDED 30 JUNE 2024**

The Trustees have pleasure in presenting their report and the unaudited financial statements for the charity for the year ended 30th June 2024. The Trustees of the charity as shown above are also the directors of the charity.

OBJECTIVES AND ACTIVITIES

The Charity's objectives are:

To advance the science, practice, and art of surgical oncology for the benefit of patients with cancer; and **to promote research, training, and education in surgical oncology** for the benefit of the public, patients and the medical community, and to disseminate the useful results of that research appropriately.

The Association serves as an umbrella organisation for professionals across all surgical cancer specialties and cancer research. Additionally, the Society is dedicated to driving innovation in cancer care, supporting the training and development of the future workforce, and ensuring our activities align with the Charity Commission's guidance on public benefit.

Portfolio of BASO Prizes and Awards

The Association is proud to offer a variety of awards aimed at inspiring our junior colleagues and fostering their passion for surgical oncology, cancer research, and patient care. For more details, visit: <https://baso.org.uk/education-training.aspx>. At our annual scientific meeting, the Society continues to present the following prestigious prizes:

- **Alan Edwards Memorial Prize** is awarded to the best poster presentation.
- **Ronald Raven Presentation Prize** is awarded to the best oral paper presentation.
- **BASO~ACS Presentation Prize**, formerly known as BJS Prize, is awarded to the best oral paper presentation. As a result of a structural change, the British Journal of Surgery Society (BJSS) ceased its support for this prize. In 2019, BASO Council unanimously decided to sponsor this prize to ensure continued existence to the BJS Paper Presentation Prize awarded at the BASO Meeting.
- **BASO Trainees (poster/oral presentation) Prize** is awarded to the best poster and oral paper presentations at the BASO Trainees Meeting.

To expand its commitment to all cancer-related professionals, BASO announced the following new prizes:

- **BASO Trainees Audit/QIP Prize** to support and encourage trainees, those involved with audit and quality improvement with a view of improving care to patients, in particular, cancer patients.
- **BASO Multidisciplinary Prize** to recognise the work done by our Non-Medical Professional colleagues in supporting cancer patients. This unique award is designed to highlight any research, audit, quality improvement, health service provision/development, cancer patient pathway study, cancer survivorship study.
- **BASO Medical Student Prize** to support and encourage medical students with an interest in surgical oncology.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)**

YEAR ENDED 30 JUNE 2024

Additionally, BASO annually offers a range of prizes to encourage and promote trainees' enthusiasm for surgical oncology. These awards are presented to the trainee who delivers the best surgical oncology presentation at various surgical specialty associations' annual scientific conferences.

Over the years, BASO has established a prestigious collection of awards, recognising surgeons for their outstanding achievements and contributions to cancer surgery, research, and education.

In addition to the **Ronald Raven Lifetime Achievement Award**, **Geoff Oates Award**, and **Uccio Querci della Rovere Award**, BASO introduced the **BASO Medal for Excellence** in 2022 to commemorate the 50th anniversary of the Association's founding. This prestigious award recognises significant contributions made by individual surgeons or teams in advancing cancer care through excellence in research, clinical practice, education, and innovation.

The **BASO Medal for Excellence**, an international accolade, will be awarded every five years, with nominations open to both members and non-members. It honours exceptional contributions to cancer surgery in the UK. BASO was proud to present the inaugural medal to Professor Freddie Hamdy in July 2022.

For more details, follow the link: <https://baso.org.uk/baso~acs-conferences/baso-50thanniversary-meeting.aspx>.

BASO Grants

BASO continues to expand its portfolio of research grants to support innovative cancer research. For more information, visit: <https://baso.org.uk/education-training.aspx>.

Ronald Raven Travelling Fellowship – Established in 1993 by the Ronald Raven Trustees in memory of Ronald W Raven, the founder of the Association, this fellowship is awarded annually. BASO continues to fund this £3,000 fellowship, supporting aspiring trainees in developing their skills and experience in surgical cancer treatment.

BASO (NIHR) Research Project Grant – As a non-commercial partner with the National Institute of Health Research (NIHR), BASO successfully ran a research project grant scheme to assist surgeons in cancer-related research. Awarded projects were eligible for Clinical Research Network Support, making them eligible for inclusion in the NIHR portfolio. In 2021, BASO launched a new Research Grant in Cancer Surgery in collaboration with the Rosetrees Trust, which replaced the BASO (NIHR) Research Project Grants in 2022.

BASO/Rosetrees Research Grants in Cancer Surgery – In celebration of BASO's 50th Anniversary, the National Committee introduced a new three-year research grant partnership with the Rosetrees Trust. This collaboration provides annual grants of up to £50,000.

The first round of grants was awarded at BASO's 50th Anniversary Celebration meeting. Successful applications will be considered for inclusion in the NIHR portfolio and are encouraged to seek support from the Royal College of Surgeons of England Surgical Interventional Trials Unit (SITU).

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)
YEAR ENDED 30 JUNE 2024**

Endorsement of Regional Events

The Association strives to engage with oncologists and related societies at the regional level. Through its network of Regional Representatives, BASO has actively supported a variety of regional and national meetings throughout this accounting year.

Engagement with Medical Students

In its commitment to nurturing the next generation of surgical oncologists, the Association has opened its Trainee membership to Foundation Year Trainees and Medical Students aspiring to pursue a career in surgical oncology. BASO provides valuable support for their surgical career development through skills courses, mentoring sessions, and portfolio guidance, leveraging its extensive network of regional representatives.

The Society also actively engages with undergraduate Medical Societies by sponsoring annual meetings with the BASO Prize and hosting sponsored lectures.

BASO Trainees Group

The BASO Trainees group has consistently broadened its reach and strengthened ties with trainee groups across the UK and Europe. These collaborations have allowed us to inspire trainees in the principles of research and clinical excellence in surgical oncology, through the sponsorship of prizes and lectures at national specialty meetings. Our Trainees group remains committed to advancing research, academic training, education and fellowship opportunities.

BASO's contribution to NICE consultations and Cancer CRGs

The Society continues to make a significant impact by providing expert advice on numerous site-specific surgical cancer consultations and guidelines, as requested by NICE. Our Council members actively contribute to various Cancer Clinical Reference Groups (CRGs), offering their specialised expertise.

Additionally, the Society maintains strong relationships with surgical societies and the Royal Colleges, while continuously seeking new opportunities for collaboration.

ACHIEVEMENTS AND PERFORMANCE

The Society remains committed to supporting the training and educational needs of our colleagues while addressing the challenges faced in the post-pandemic landscape. BASO has proven the value of a unified umbrella organisation, and is actively growing its membership, expanding research collaborations through grants, and supporting educational events. With steady financial health, the Society continues to deliver successful educational meetings and initiatives.

BASO Annual Scientific Meeting

BASO 2023 delivered an exceptional program, featuring a distinguished lineup of national and international experts in cancer surgery. Themed 'Clinical & Research Excellence,' the meeting was led by BASO Immediate Past President Mr Zaed Hamady, Meeting Secretary Professor Jim Khan, and Deputy Meeting Secretary Professor Jayant Vaidya, showcasing excellence across all aspects.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)
YEAR ENDED 30 JUNE 2024**

To enhance member benefits, registration fees were subsidised for both BASO and Trainee members. Additionally, the BASO Trainees Day was held virtually, providing a valuable experience at no cost for those who registered for both days of the main BASO Meeting. This initiative was designed to maximise accessibility and participation among our valued members.

The conference was structured with dedicated plenary sessions and roundtable discussions across a wide range of disciplines, fostering a network of professionals to exchange ideas and explore learning opportunities. Feedback from surgical delegates has been overwhelmingly positive, especially with the return to in-person meetings. This format provided broader networking opportunities, particularly benefiting our junior colleagues.

The program featured a distinguished lineup of speakers and engaging sessions, including hot debates, plenary awards, abstract prizes, specialty updates, keynote talks, and the latest advancements in surgical education. Notable guest speakers included Professor John Marks, Professor Susan Moug, Professor Paul H. Sugarbaker, Professor Isabel-Teresa Rubio, Professor Lynda Wyld, and Miss Rachel Hargest, among others. The focus was on best practices in surgical oncology, offering valuable insights into surgical cancer research and management across various specialties. The meeting provided excellent learning opportunities for both experienced consultants and trainee - whether they are pursuing a career in surgical oncology or exploring other surgical disciplines.

The BASO Trainees Day featured several prominent speakers who provided valuable insights across a wide range of topics. The program offered fresh perspectives on achieving excellence in both clinical work and research, guiding future careers in surgical oncology.

Approximately 120 abstracts were submitted, with 7 abstract prizes awarded for outstanding presentations. The meeting also featured several prestigious eponymous lifetime achievement awards and orations, honouring some of the leading surgeons of our time.

The Association is committed to building on the success of this program and ensuring the financial sustainability of future BASO meetings.

European Journal of Surgical Oncology

The **EJSO**, co-owned by BASO and ESSO, continues to thrive with improved submission quality and increased article downloads. The 2023 impact factor, released in June, has risen to 3.62 (for more details, visit: https://journalinsights.elsevier.com/journals/0748-7983/impact_factor_5_year). This significant increase in citations is a testament to the outstanding work of the editorial team, led by our past President, Professor Riccardo Audisio (Editor-in-Chief).

Network and links with other organisations

The Association is actively developing and strengthening connections with other specialties. This includes establishing membership ties, offering consultations, providing mentoring opportunities, and forming partnerships for future joint conferences.

Meanwhile, the BASO Trainees Group is expanding its network and is represented on the ASiT Council. The group awards Trainee Prizes of £100 each for the most outstanding surgical oncology presentations at the Annual ASiT Conference and the SCTS Annual Meetings.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)**

YEAR ENDED 30 JUNE 2024

To foster collaborative efforts, BASO Trainees has partnered with the Dukes Club and Roux Club, and recently collaborated with BONUS and SCALPEL groups to engage medical students interested in pursuing careers in surgical oncology.

European Society of Surgical Oncology

BASO maintains a strong partnership with its European sister society, ESSO. Under the Memorandum of Understanding between the two societies, BASO members benefit from full standard membership privileges with ESSO. This includes reduced registration rates for the ESSO Annual Conference, courses, and training programs. BASO members also have the opportunity to apply for an international career development program and gain access to members-only areas on the ESSO website. Additionally, BASO members now have voting rights at the ESSO General Assembly.

National Clinical Guidelines

BASO plays a significant role in the development and updating of National Clinical Guidelines. BASO council and members are appointed as Specialist Advisors for NICE's Interventional Procedure Programmes. Additionally, BASO Trustees actively contribute to various consultations and are engaged members of multiple Cancer Commissioning Groups.

All-Party Parliamentary Group on Cancer

The BASO sits as a stakeholder at the All-Party Parliamentary Group on Cancer. As the sole organisation representing the surgical community in this group, BASO is well-positioned to engage with policymakers and advocate effectively for the interests of oncology surgeons.

Health and Social Care Committee Cancer Services Expert Panel

BASO Trustees represented at the roundtable meeting to share views on a number of pledges that government has made to improve cancer services in England. It was a productive meeting and helped voice BASO's concerns, and raised the Society's profile and engagement.

Cancer Services Committee

BASO has chaired the Royal College of Surgeons of England's Cancer Services Committee (CSC), which includes representatives from all surgical disciplines. This committee has served as a vital platform for articulating the collective views of the surgical community on cancer care issues. It has provided a forum for Surgical Oncology to present a unified stance on major concerns and has included contributions from various surgical societies, Royal Colleges, patient liaison groups, and Macmillan.

In May 2022, the CSC was temporarily paused to review its remit, functionality, and representation to the Royal College of Surgeons of England Council. Following discussions with the College, BASO Council is pleased to announce the reinstatement of the CSC. This committee remains essential for communicating a cohesive perspective on cancer care and for addressing significant issues related to the commissioning of cancer services.

We believe that the CSC's reinstatement is a significant step forward in advancing BASO's collective efforts in cancer care.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)
YEAR ENDED 30 JUNE 2024**

BASO Publications

This year, BASO supported the Health Awareness: Innovations in Oncology and Imaging campaign that launched on 28th March within the Guardian and online at:

<https://www.healthawareness.co.uk/campaign/oncology/>.

BASO~ACS contributed with an article on ["Personalising breast cancer care: ways to minimise negative impacts of treatment"](#). *Discover the latest in personalised breast cancer care and treatment options. Learn about imaging advancements and targeted therapies for improved outcomes.*

BASO Endorsed Meetings

This year, BASO endorsed the following events and meetings:

- SACLPEL, Buckingham University's Medical Student Meeting – September 2023
- Surgical Oncology in Emergency Setting – September 2023
- BASO @ Association of Surgeons of India Conference – December 2023
- 8th Portsmouth Colorectal Congress – June 2024

BASO~ACS remains committed to advancing cancer treatment, research, patient care, and the education and training of the next generation of oncologists.

FINANCIAL REVIEW

Membership

Membership of the Association has remained stable throughout the year. In response to rising operational costs due to inflation, a nominal increase in subscription fees for all categories was unanimously approved at the 2022 AGM. This adjustment ensures we can effectively manage the growing expenses.

As agreed at the 2017 AGM, BASO offers a 50% discount on Full Membership for a period of two years to BASO Trainees members who have completed their training. This benefit is available to those who have maintained continuous membership for two consecutive years as paying members.

EJSO

Profits from the *EJSO* are applied to offset the cost of membership subscriptions to the journal, which are included in the final reconciliation.

In 2023, the journal generated a healthy profit for BASO~ACS, with an income of £110,212 after deducting BASO's membership subscription for the year.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)**

YEAR ENDED 30 JUNE 2024

Revenue from electronic institutional subscriptions, through e-only licenses and collections, continues to grow steadily. However, as anticipated, print revenues have declined as more customers opt for online access. The number of authors choosing to fund Open Access articles has significantly increased, leading to substantial growth in revenue from this source. BASO members continue to enjoy a 30% reduction in Open Access fees.

It is hoped that the EJSO will continue to grow under the editorship of Professor Riccardo A Audisio.

BASO Grants and Prizes

1. BASO/Rosetrees Research Grants in Cancer Surgery 2023 is awarded to:

- Mr Chase Ng for study '*Low-Cost Virtual Reality Surgical Simulator Versus Traditional Surgical Training in Training Novice Surgeons to Perform Radical Abdominal Hysterectomy for Early-Staged Cervical Cancer: A Feasibility Randomised Clinical Trial*'.
- Miss Sarah Epton for study '*Improving Oesophago-Gastric Cancer Care by Identifying the Crucial Quality Indicators Necessary to Achieve Optimal Outcomes*'.

2. Ronald Raven Travelling Fellowship Grant 2023 – Unfortunately, due to a lack of suitable applications, no travelling fellowships were awarded in 2023.

3. BASO Trainees Prize were awarded at the following external meetings:

- SCTS Annual Scientific Meeting
- ASiT Annual Conference
- BONUS Annual Meeting
- SCALPEL Meeting
- BASO Trainees Research Forum

BASO Annual Meeting 2023

BASO Trustees firmly believe that the Charity continues to fulfil its objectives by promoting and supporting advancements in surgical oncology research and education, as demonstrated by yet another successful meeting.

The meeting was supported by industry sponsorship; however, due to higher logistical costs associated with hosting in London, the 2023 Annual Conference incurred a planned loss. This was accounted for, as the National Committee made a strategic decision to fully sponsor the trainees' meeting and offer subsidised registration for junior members. It was agreed that a successful meeting was essential to fulfilling our charitable aims and would likely contribute to increased membership in the Society.

The conference elevated the Association's presence in cancer research, fostered engagement with various organisations and groups, and provided an excellent networking platform for BASO members, leading to the recruitment of new members. The Association maintains strong reserves and has secured a new income stream through the EJSO, allowing us to continue investing in education, training, and research through our Annual Conferences. However, we aim to transition towards a cost-neutral financial model in the future.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)
YEAR ENDED 30 JUNE 2024**

Reserves Policy

BASO ~ ACS holds a sufficient reserve to allow the society to meet financial obligations in the event of a financial loss following an annual conference, to maintain the low level of conference fees for delegates and to obviate the need for increases in Membership fees. The level of reserves, and income from conferences and subscriptions, is crucial to the Association's work and objectives, and is monitored carefully to ensure a balance between a secure financial position for the Association and minimal costs to Members and potential Members.

Investment Policy

The Trustees have power under the Articles to invest funds in the same manner and subject to the same conditions as the Trustees of a trust are permitted to do by the Trustee Act 2000. The Association currently holds its reserves across three deposit accounts: BASO ~ ACS holds reserves in a Scottish Widows 90-day notice account; an instant access account with Lloyds TSB; and a further instant access account with Virgin Money. BASO Trustees are looking into new investment opportunities for the Association's reserves.

STRUCTURE, GOVERNANCE AND MANAGEMENT

On 1st July 2010 a transfer was made from the unincorporated charity, BASO ~ The Association for Cancer Surgery, to the company limited by guarantee of the same name (Company number: 7225131, Limited by Guarantee and Registered as Charity No 1136067). The company was incorporated on the 15th April 2010 when new Articles were established. Simultaneous transfers were made to the new Association of Breast Surgery, which is also a company limited by guarantee (Company No 7207053 and Registered as Charity 1135699). The two Associations are thus legally independent of each other, with a service agreement between the two Associations to allow for the provision of a shared office and administration. Whilst the degree of separation has increased over time to allow both Associations to evolve and develop their individual identities, they share many goals and continue to work cooperatively together.

In May 2020, both Associations separated their joint database and IT services while agreeing to retain historical records of joint members, as well as members of ABS who attended BASO events and vice versa. The service agreement is subject to periodic review to ensure its continued relevance and fairness to both Associations. At this stage, no further significant changes are anticipated.

The Ordinary Members of the BASO~ACS National Committee and the Honorary Officer position of Vice President (who are also Trustees and Directors) are elected by a ballot of the Membership of the Association, following a 'Call for Nominations'. Officer posts (bar the Vice President position) are notified to the Membership by a call for nominations, followed by a ballot of Trustees if there is more than one candidate. All Honorary Officers are also Trustees and Directors. All appointments are confirmed by the Membership at the AGM.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)**

YEAR ENDED 30 JUNE 2024

BASO~ACS has National Committee meetings four times a year. The main business of BASO~ACS is decided upon at its National Committee meetings. Decisions in-between times are made by phone or e-mail communication between the Honorary Officers, with day-to-day issues being dealt with by the Association Manager in liaison with the Honorary Officers. The Trustees/Directors regularly review the major risks that the charity faces and its reserve policy, combined with an annual internal audit of the controls over key financial systems, which are designed to provide sufficient resources in the event of adverse conditions. No major risks have been identified by the Trustees during the year.

The Trustees pay due regard to the Charity Commission's guidance on public benefit when deciding what activities the Charity should undertake.

PLANS FOR THE FUTURE

Expanding core membership and the range of specialisms represented were outlined as key objectives for 2023-24. Although overall growth has not materialized, membership numbers have remained stable. The Trustees are actively working to strengthen ties with other Associations, many of which have been invited to nominate observers to Council meetings. In turn, BASO has offered to send observers to their meetings, aiming to enhance communication and understanding in areas of shared interest. Several Associations have shown interest, and the Trustees look forward to reporting progress in this area. The current Trustees represent a wide array of specialisms, bringing a valuable breadth of experience and perspectives to the steering process.

BASO Trustees also plan to establish affiliation support for smaller, complex cancer surgical groups by offering them affiliation to BASO membership and endorsement of their meetings. This will further expand the Association's role as the umbrella Society for all cancer surgeons.

BASO made significant contributions to consultations organized by NICE. Trustees are actively building collaborations with Royal Colleges, Cancer Commissioning Boards, Public Health England, the GMC, and other stakeholders. These partnerships aim to share knowledge, stimulate debate, and enhance best practices for the benefit of cancer patients.

In addition, BASO will continue funding research grants in partnership with the Rosetrees Trust to support surgical oncology research. This initiative aims to broaden the scope of surgical research, with shortlisted studies eligible for inclusion in the NIHR portfolio.

BASO will extend its sponsorship and support to regional meetings and Student Surgical Societies, further fostering engagement.

BASO Trainees membership is now open to Medical Students and Foundation Year Trainees interested in surgical oncology. The goal is to support their education, training, and career development in cancer surgery.

As healthcare evolves and training pressures increase, BASO Trainees aim to improve the training experience and professional competence of surgical trainees interested in oncology, particularly in academic and research domains.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)**

YEAR ENDED 30 JUNE 2024

This report has been prepared having taken advantage of the small companies exemption in the Companies Act 2006.

Approved by the Trustees on 4 November 2024 and signed on their behalf by:

Michael Shackcloth

.....
Mr Michael Shackcloth
Honorary Treasurer

COMPANY LIMITED BY GUARANTEE
INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES
YEAR ENDED 30 JUNE 2024

I report to the charity trustees on my examination of the accounts of the company for the year ended 30 June 2024 which are set out on pages 13 to 20.

Responsibilities and basis of report

As the charity trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Alex Stone

.....
Alex Stone FCCA

Edmund Carr LLP
146 New London Road
Chelmsford
CM2 0AW

6 February 2025

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

**STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND
EXPENDITURE ACCOUNT)**

YEAR ENDED 30 JUNE 2024

		Unrestricted Funds	Restricted Funds	Total Funds 2024	Total Funds 2023
	Note	£	£	£	£
INCOME from:					
Donations - Rosetrees Trust		-	25,000	25,000	25,000
Charitable activities:					
Members' subscriptions		34,726	-	34,726	34,442
BASO Conference and Meetings	2	33,780	-	33,780	38,445
Publications - EJSO		120,040	-	120,040	111,143
Other trading activities		-	-	-	-
Investments	3	2,676	1,831	4,507	1,497
TOTAL INCOME		<u>191,222</u>	<u>26,831</u>	<u>218,053</u>	<u>210,527</u>
EXPENDITURE on:					
Charitable activities:					
Subscriptions - ESSO		9,773	-	9,773	9,165
BASO Conference and Meetings	2	51,038	-	51,038	65,896
Publications - EJSO		9,828	-	9,828	12,509
Fellowships & awards	4	26,418	24,500	50,918	57,027
National Committee and support costs	5	99,464	-	99,464	95,296
TOTAL EXPENDITURE		<u>196,521</u>	<u>24,500</u>	<u>221,021</u>	<u>239,893</u>
NET INCOME/(EXPENDITURE)		(5,299)	2,331	(2,968)	(29,366)
Transfers between funds		-	-	-	-
NET MOVEMENT IN FUNDS		(5,299)	2,331	(2,968)	(29,366)
RECONCILIATION OF FUNDS					
Total funds brought forward		254,485	26,273	280,758	310,124
Total funds carried forward		<u>249,186</u>	<u>28,604</u>	<u>277,790</u>	<u>280,758</u>

The charity has no recognised gains or losses other than the results for the period as set out above.

The notes on pages 15 to 20 form part of these financial statements.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
BALANCE SHEET
AS AT 30 JUNE 2024**

		2024		2023	
	Note	£	£	£	£
FIXED ASSETS					
Tangible assets	10		292		389
CURRENT ASSETS					
Debtors	11	43,986		10,685	
Cash at bank		335,855		356,089	
		<u>379,841</u>		<u>366,774</u>	
CREDITORS: Amounts falling due within one year	12	<u>(102,343)</u>		<u>(86,405)</u>	
NET CURRENT ASSETS			277,498		280,369
TOTAL ASSETS LESS CURRENT LIABILITIES/ NET ASSETS			<u>277,790</u>		<u>280,758</u>
FUNDS					
Unrestricted	13		249,186		254,485
Restricted	14		28,604		26,273
TOTAL FUNDS			<u>277,790</u>		<u>280,758</u>

For the year ending 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006 and with the Financial Reporting Standard (FRS102) (effective 1 January 2019).

These financial statements were approved by the Trustees on 4 November 2024 and are signed on their behalf by:

Michael Douek
.....
PROFESSOR MICHAEL DOUEK

Michael Shackcloth
.....
MR MICHAEL SHACKCLOTH

Company Registration Number: 7225131

The notes on pages 15 to 20 form part of these financial statements.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2024

1. ACCOUNTING POLICIES

Basis of accounting

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

BASO - The Association for Cancer Surgery meets the definition of a public benefit entity under FRS102. Assets and Liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes. The financial statements are prepared in sterling, which is the functional currency of the charity, and rounded to the nearest £. The charity is a company limited by guarantee.

Going Concern

The financial statements have been prepared on a going concern basis as the Trustees believe that no material uncertainties exist. The Trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern.

Incoming Resources

Income from conferences held during the year is accounted for on an accruals basis. Membership subscriptions are recognised on receipt.

Resources Expended

All expenditure is accounted for on an accruals basis and includes VAT as the charity is not VAT registered. The majority of costs are attributable to specific charitable activities (ie conferences/awards). Fellowships and awards are accounted for in the period in which they are notified to the recipient. Governance costs are associated with the governance arrangements of the charity.

Debtors and creditors

Trade and other debtors are recognised at the settlement amount due. Creditors are recognised at their settlement amount.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and deposits.

Fixed Assets and Depreciation

Fixed assets are shown at historical cost. Expenditure on tangible fixed assets is capitalised. The cost of other items is written off as incurred.

Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:

Computer equipment	25% reducing balance
Fixtures & fittings	25% reducing balance

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2024**

ACCOUNTING POLICIES continued

Fund accounting

Funds held by the charity are either:

Unrestricted general funds – these are funds which can be used in accordance with the charitable objects at the discretion of the trustees.

Restricted funds – these are funds that can only be used for particular restricted purposes within the objects of the charity.

2. CHARITABLE ACTIVITIES

SCIENTIFIC CONFERENCE AND MEETINGS

	Unrestricted Funds	Restricted Funds	Total Funds 2024	Total Funds 2023
	£	£	£	£
Income				
BASO Conference Fees	31,780	-	31,780	28,945
Lecture grants	2,000	-	2,000	2,000
Other meetings	-	-	-	7,500
	<u>33,780</u>	<u>-</u>	<u>33,780</u>	<u>38,445</u>
Expenditure				
BASO Conference	50,899	-	50,899	43,013
BASO 50th Anniversary Meeting	-	-	-	12,456
Other meetings	139	-	139	10,427
	<u>51,038</u>	<u>-</u>	<u>51,038</u>	<u>65,896</u>

3. INVESTMENT INCOME

All of the charity's investment income arises from interest bearing deposit accounts.

4. FELLOWSHIPS & AWARDS

	Unrestricted Funds	Restricted Funds	Total Funds 2024	Total Funds 2023
	£	£	£	£
Ronald Raven Prize	-	600	600	600
Ronald Raven Travel Scholarships	-	-	-	3,000
Alan Edwards Memorial Fund	-	400	400	400
BASO/Rosetrees Research Grant	25,000	25,000	50,000	50,000
Other awards and medals	1,418	-	1,418	3,027
Unclaimed awards released	-	(1,500)	(1,500)	-
	<u>26,418</u>	<u>24,500</u>	<u>50,918</u>	<u>57,027</u>
2023	28,027	29,000	57,027	

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2024

5. NATIONAL COMMITTEE & SUPPORT COSTS

	Unrestricted Funds	Restricted Funds	Total Funds 2024	Total Funds 2023
	£	£	£	£
Staff salaries and pension costs	55,390	-	55,390	53,206
National committee costs	12,784	-	12,784	2,058
Other support costs	19,042	-	19,042	16,352
Governance costs (note 6)	12,248	-	12,248	23,680
	<u>99,464</u>	<u>-</u>	<u>99,464</u>	<u>95,296</u>
2023	95,296	-	95,296	

6. GOVERNANCE COSTS

	Unrestricted Funds	Restricted Funds	Total Funds 2024	Total Funds 2023
	£	£	£	£
Accounting and payroll services	4,123	-	4,123	3,919
Independent examination fee	650	-	650	620
Fees payable to independent examiner	4,773	-	4,773	4,539
Bank charges	510	-	510	389
Legal and professional fees	6,965	-	6,965	18,752
	<u>12,248</u>	<u>-</u>	<u>12,248</u>	<u>23,680</u>

7. STAFF COSTS AND EMOLUMENTS

Total staff costs were as follows:	2024	2023
	£	£
Wages & salaries	49,500	48,726
Pension costs (defined contribution scheme)	5,890	4,480
	<u>55,390</u>	<u>53,206</u>

Particulars of employees:

The average number of employees during the year was 1, (full-time equivalent - 0.8)
(2023 - 1 employee and 0.8 FTE)

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2024**

8. NET OUTGOING RESOURCES FOR THE YEAR

	2024	2023
	£	£
This is stated after charging:		
Depreciation	97	177

9. TRUSTEES' REMUNERATION

None of the Trustees were paid any remuneration by the Association during the period.
Trustees are reimbursed reasonable expenses incurred when acting on behalf of the company.
Expenses totalling £4,895 were reimbursed to 11 trustees during the period
(2023 - £848 to 5 Trustees).

10. TANGIBLE FIXED ASSETS

	Computer equipment £	Fixtures & fittings £	Total £
COST			
At 1 July 2023	2,691	611	3,302
Additions	-	-	-
Disposals	-	-	-
At 30 June 2024	<u>2,691</u>	<u>611</u>	<u>3,302</u>
DEPRECIATION			
At 1 July 2023	2,302	611	2,913
Charge for the year	97	-	97
Disposals	-	-	-
At 30 June 2024	<u>2,399</u>	<u>611</u>	<u>3,010</u>
NET BOOK VALUE			
At 30 June 2024	<u>292</u>	<u>-</u>	<u>292</u>
At 30 June 2023	<u>389</u>	<u>-</u>	<u>389</u>

11. DEBTORS

	2024	2023
	£	£
Trade debtors	410	-
Prepayments and accrued income	24,656	10,685
Other Debtors	18,920	-
	<u>43,986</u>	<u>10,685</u>

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS**

YEAR ENDED 30 JUNE 2024

12. CREDITORS: Amounts falling due within one year

	2024	2023
	£	£
Trade creditors	2,301	-
Grants payable	30,000	20,715
Accruals	8,650	5,602
Deferred income	61,392	60,088
	<u>102,343</u>	<u>86,405</u>

Deferred income relates to EJSO royalties received in advance for the following period.

13. UNRESTRICTED FUNDS

Current year	Movement in resources:				Balance at 30/06/2024
	Balance at 01/07/2023	Incoming	Outgoing	Transfers	
	£	£	£	£	£
General unrestricted funds	<u>254,485</u>	<u>191,222</u>	<u>(196,521)</u>	<u>-</u>	<u>249,186</u>
Prior year	Balance at 01/07/2022	Incoming	Outgoing	Transfers	Balance at 30/06/2023
	£	£	£	£	£
General unrestricted funds	<u>280,620</u>	<u>184,758</u>	<u>(210,893)</u>	<u>-</u>	<u>254,485</u>

14. RESTRICTED FUNDS

Current year	Movement in resources:				Balance at 30/06/2024
	Balance at 01/07/2023	Incoming	Outgoing	Transfers	
	£	£	£	£	£
a) Alan Edwards Memorial Fund	4,931	373	(400)	-	4,904
b) Ronald Raven Prize Fund	1,567	270	(600)	-	1,237
c) Ronald Raven Travelling Fund	19,775	1,188	1,500	-	22,463
d) BASO/Rosetrees Fund	-	25,000	(25,000)	-	-
	<u>26,273</u>	<u>26,831</u>	<u>(24,500)</u>	<u>-</u>	<u>28,604</u>

a)-c) Prize funds: An award made from the Ronald Raven Travelling Fund in 2021 was not claimed by the recipient and has been withdrawn.

d) Donations from the Rosetrees Trust towards the joint BASO/Rosetrees Research grants.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2024**

14. RESTRICTED FUNDS

<i>Prior year</i>	<i>Movement in resources:</i>				<i>Balance at 30/06/2023</i>
	<i>Balance at 01/07/2022</i>	<i>Incoming</i>	<i>Outgoing</i>	<i>Transfers</i>	
	£	£	£	£	£
a) <i>Alan Edwards Memorial Fund</i>	5,178	153	(400)	-	4,931
b) <i>Ronald Raven Prize Fund</i>	1,876	291	(600)	-	1,567
c) <i>Ronald Raven Travelling Fund</i>	22,450	325	(3,000)	-	19,775
d) <i>BASO/Rosetrees Fund</i>	-	25,000	(25,000)	-	-
	<u>29,504</u>	<u>25,769</u>	<u>(29,000)</u>	<u>-</u>	<u>26,273</u>

15. ANALYSIS OF NET ASSETS (between restricted and unrestricted funds)

<i>Current year</i>	<i>Tangible fixed assets</i>	<i>Other net assets</i>	<i>Total</i>
	£	£	£
Restricted funds	-	28,604	28,604
Unrestricted funds	292	248,894	249,186
	<u>292</u>	<u>277,498</u>	<u>277,790</u>
<i>Prior year</i>	<i>Tangible fixed assets</i>	<i>Other net assets</i>	<i>Total</i>
	£	£	£
<i>Restricted funds</i>	-	26,273	26,273
<i>Unrestricted funds</i>	389	254,096	254,485
	<u>389</u>	<u>280,369</u>	<u>280,758</u>

16. COMPANY LIMITED BY GUARANTEE

The company is controlled by its members. Every member of the company undertakes to contribute to the assets of the Company in the event of the same being wound up during the time he/she is a member, or within one year afterwards, for the payments of the debts and liabilities of the company contracted before the time at which he/she ceases to be a member and of the costs, charges and expenses of winding up the same, and for the adjustments of the rights of the contributors among themselves such amount as may be required not exceeding one pound.

17. RELATED PARTY TRANSACTIONS

There were no related party transactions that require disclosure during the year other than the reimbursement of expenses to Trustees, disclosed in Note 9.

Accounts

COMPANY REGISTRATION NUMBER : 7225131

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
UNAUDITED FINANCIAL STATEMENTS
FOR
YEAR ENDED 30 JUNE 2023**

Charity Number : 1136067



Edmund Carr LLP
Chartered Accountants
146 New London Road
Chelmsford
Essex
CM2 OAW

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2023

CONTENTS	PAGE
Company information	1
Trustees' annual report	2
Independent Examiner's report to the Trustees	12
Statement of financial activities	13
Balance sheet	14
Notes to the financial statements	15

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

COMPANY INFORMATION

YEAR ENDED 30 JUNE 2023

Charity Number	1136067
Company Number	7225131
Registered Office	38-43 Lincoln's Inn Fields London WC2A 3PE

THE TRUSTEES

The Trustees of the charity are also the directors of the charity.

The Trustees who served the charity during the year were as follows:

Mr Zaed Hamady	President
Professor Michael Douek	Vice President
Professor Anant Desai	Honorary Secretary
Mr Michael Shackcloth	Honorary Treasurer
Mr John Whiting	EJSO Representative
Professor Jim Khan	Meeting Secretary
Mr Avi Agrawal	
Mr Edmund Leung	(Resigned 20/11/2022)
Professor Derek Manas	
Mr Aaron Quyn	
Mr Paul Skaife	
Mrs Abigail Tomlins	(Appointed 20/11/2022)
Professor Jayant Vaidya	(Deputy Meeting Secretary)

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT
YEAR ENDED 30 JUNE 2023**

The Trustees have pleasure in presenting their report and the unaudited financial statements for the charity for the year ended 30th June 2023. The Trustees of the charity as shown above are also the directors of the charity.

Objectives and Activities

The Charity's objectives are:

To advance the science, practice, and art of surgical oncology for the benefit of patients with cancer; and **to promote research, training, and education in surgical oncology** for the benefit of the public, patients and the medical community, and to disseminate the useful results of that research appropriately.

The Association serves as an umbrella organisation for professionals in all surgical cancer specialties and cancer research. In addition, the Society focuses on innovation in cancer care, support the training and development of future workforce, and carefully consider the Charity Commission's guidance on public benefit when determining our activities.

Portfolio of BASO Prizes and Awards

The Association takes immense pride in its array of awards dedicated to inspiring our junior colleagues and nurturing their passion for surgical oncology, cancer research and patient care. Follow link for more details: <https://baso.org.uk/education-training.aspx>. The Society continues awarding the following prizes at its annual scientific meeting:

- **Alan Edwards Memorial Prize** is awarded to the best poster presentation.
- **Ronald Raven Presentation Prize** is awarded to the best oral paper presentation.
- **BASO~ACS Presentation Prize**, formerly known as BJS Prize, is awarded to the best oral paper presentation. As a result of a structural change, the British Journal of Surgery Society (BJSS) ceased its support for this prize. In 2019, BASO Council unanimously decided to sponsor this prize to ensure continued existence to the BJS Paper Presentation Prize awarded at the BASO Meeting.
- **BASO Trainees (poster/oral presentation) Prize** is awarded to the best poster and oral paper presentations at the BASO Trainees Meeting.

To expand its commitment to all cancer-related professionals, BASO announced the following new prizes:

- **BASO Trainees Audit/QIP Prize** to support and encourage trainees, those involved with audit and quality improvement with a view of improving care to patients, in particular, cancer patients.
- **BASO Multidisciplinary Prize** to recognise the work done by our Non-Medical Professional colleagues in supporting cancer patients. This unique award is designed to highlight any research, audit, quality improvement, health service provision/development, cancer patient pathway study, cancer survivorship study.
- **BASO Medical Student Prize** to support and encourage medical students with an interest in surgical oncology.

In addition, BASO annually provides a range of prizes to foster and promote trainee's enthusiasm for surgical oncology. These prizes are awarded to the trainee who delivers the best surgical oncology presentation at the various surgical specialty associations' annual scientific conferences.

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2023

Over the years, BASO has curated a prestigious collection of Awards presented to surgeons in recognition of their exceptional accomplishments and contributions to cancer surgery; its research and education.

In addition to **Ronald Raven Lifetime Achievement Award**, **Geoff Oats Award** and **Uccio Querci della Rovere Award**, this year BASO inaugurated - **BASO Medal for Excellence** to mark the 50th Anniversary of the founding of the Association. The British Association of Surgical Oncology Medal for Excellence is presented to acknowledge the significant contributions made by individual surgeon or team in advancing cancer care, excelling in research, clinical practice, education and innovation. This prestigious international award will be presented every five years, welcoming nominations from both members and non-members of the Association, in recognition of their remarkable contributions to cancer surgery in the UK. BASO took great pride in awarding the inaugural medal to Professor Freddie Hamdy in July 2022. Follow link for more details: <https://baso.org.uk/baso~acs-conferences/baso-50thanniversary-meeting.aspx>

BASO Grants

BASO continues growing its portfolio of research grants to support research. Follow link for more details: <https://baso.org.uk/education-training.aspx>

Ronald Raven Travelling Fellowship – was endowed in 1993 by the Ronald Raven Trustees in memory of Ronald W. Raven, the Founder of the Association. BASO Continues to fund and award this fellowship, which has now increased to £3,000, each year to aspiring trainees to support them to expand their skills and experience in the surgical cancer treatment.

BASO (NIHR) Research Project Grant - BASO is a non-commercial partner with the National Institute of Health Research (NIHR) and delivered a successful annual research project grant scheme to assist surgeons in undertaking research projects related to surgically linked cancer care. This grant was open for discrete projects and the studies awarded this grant are automatically eligible for consideration for the Clinical Research Network Support, thereby, are considered for being the portfolio studies. In 2021, BASO announced a new Research Grant in Cancer Surgery, in collaboration with the Rosetrees Trust which will supplant the BASO (NIHR) Research Project Grants starting from 2022.

BASO/Rosetrees Research Grants in Cancer Surgery – To commemorate BASO's 50th Anniversary, the BASO National Committee announced a new initiative, a three-year research grants (in cancer surgery) partnership with the Rosetrees Trust. This collaborative effort will award research grants of up to £50,000 annually, with matching funds provided by the Rosetrees Trust.

The first round of the grants were awarded at BASO's 50th Anniversary Celebration meeting. Successful applications will be eligible for inclusion in the NIHR portfolio and are encouraged to gain support from a Royal College of Surgeons of England Surgical Interventional Trials Unit (SITU).

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)
YEAR ENDED 30 JUNE 2023**

Endorsement of Regional Events

The Association aspires to engage with oncologists and Societies on the regional level. Through its network of Regional Representatives, BASO has supported various regional and national meetings this accounting year.

Engagement with Medical Students

In the spirit of encouraging the future generation of surgical oncologists, the Association has opened its Trainees membership to Foundation Year Trainees and Medical Students, those wishing to pursue surgical oncology. BASO aims to offer support with their surgical career by providing skills courses, mentoring sessions, and guiding surgical portfolio via our wealth of regional representatives.

The Society is actively engaging with undergraduate Medical Societies by sponsoring their annual meeting with BASO Prize and sponsored lectures.

BASO Trainees Group

The BASO Trainees group has continually expanded its horizons and strengthened connections with trainees groups across UK and Europe. These collaborations have enabled us to inspire trainees in tenets of research and clinical excellence in surgical oncology, achieved through the sponsorship of prizes and sponsored lectures at national specialty meetings. Our Trainees remains dedicated to promoting research, academic training, and fellowships.

BASO's contribution to NICE consultations and Cancer CRGs

The Society continues to make its mark and offers expert advice on numerous site-specific Surgical Cancer consultations and guidelines as requested by NICE. Our Council members sit on various Cancer CRG's, offering expert advice.

Overall, the Society maintains robust relationships with all the surgical societies and the Royal Colleges while actively seeking collaborative opportunities.

Achievements and Performance

The Society continues to support the training and educational needs of our colleagues and address the challenges faced post pandemic. BASO has demonstrated the need for an umbrella organisation to speak with one voice, and is growing its membership, maintained steady finances and returned to a successful in-person meeting post pandemic.

BASO Annual Scientific Meeting

It was exciting to return to an in-person BASO Annual Scientific Meeting in 2022 after what has undoubtedly been a challenging couple of years for all. The meeting was themed "multidisciplinary cancer management- evolving role of surgical oncology", and was delivered under the leadership of BASO President, Mr Zaed Hamady, along with Professor Jim Khan as the Meeting Secretary and Professor Jayant Vaidya as the Deputy Meeting Secretary.

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)
YEAR ENDED 30 JUNE 2023**

The conference was designed with dedicated plenary sessions and roundtable discussion style sessions for the wide range of disciplines, bringing a network of professionals cross-referencing ideas and learning opportunities. The feedback from surgical delegates has been extremely positive, especially with return to in-person meeting, offering a much broader networking opportunity, particularly for our junior colleagues.

The programme was facilitated by the National and International experts in the field of cancer surgery. Guest speakers included Professor Mike Dixon, Professor Mark Emberton, Professor George Hanna, Professor Richard Heald, Professor Isabel-Teresa Rubio, Miss Jennifer Rusby, Professor Peter Sagar, Professor Irving Taylor, and many more. The programme focussed on the best of practice of surgical oncology. The meeting, provided a great opportunity to learn about surgical cancer research and management in a wide range of surgical specialties. There was an excellent programme for both experienced consultants in surgery and for trainees - both those trainees interested in a surgical oncology career and also those not yet committed to a particular surgical discipline.

The BASO Trainees Day had several prominent speakers who gave us an insight into a full range of topics. These include the role of technology in improving survival and cancer patient outcomes, key issues in peri-operative care of cancer patients, an MDT round table discussion on challenging clinical cases and a session on how to develop a career in cancer surgery.

Approx. 100 abstracts were received, and 7 abstract prizes were awarded for best abstract presentations. The meeting also saw several prestigious eponymous lifetime achievement awards and orations, including the RCS's Sir Stanford Cade Lecture, given to some of the leading surgeons of our times.

The Association aspires to continue building on the success of this programme and making BASO meetings financially sustainable.

BASO's Golden Jubilee Celebrations

BASO, as you know, is one of the oldest cancer surgery associations, founded in 1971 to further the philosophy that the management of malignant disease was becoming a multidisciplinary challenge. The association has since developed and expanded to advance the science, practice, and art of surgical oncology for the benefit of patients and relatives with cancer; and to promote research, training, and education in surgical oncology and to disseminate the useful results of that research appropriately.

It was indeed honour to celebrate BASO's 50th anniversary alongside esteemed guests and members on 2nd July 2022. We extend our heartfelt gratitude to everyone who contributed to the success of BASO's Golden Jubilee. The Society has achieved an impressive amount in its 50 years, it was a privilege to recognise the achievements of our dedicated colleagues, members, juniors and friends who have played a pivotal role in shaping the Society's success.

European Journal of Surgical Oncology

The EJSO, co-owned by BASO and the ESSO continues to go from strength to strength with a rise in the quality of submission and article downloads. The 2022 impact factor were released earlier in June.

The EJSO impact factor has moved to 3.8. (Follow link for more details:

https://journalinsights.elsevier.com/journals/0748-7983/impact_factor_5_year). There has been a remarkable jump in citations and credit must be given to the editorial team led by our past President Professor Riccardo Audisio (Editor in Chief).

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2023

Network and links with other organisations

The Association continues to develop and strengthen its links with other specialties, including establishing membership ties with other specialties, offering consultations, providing mentoring opportunities, and forging partnerships for joint conferences in future.

Simultaneously, the BASO Trainees Group is also proactively expanding its network and holds representation on the ASiT Council. BASO Trainees maintains a portfolio of Trainees Prizes of £100 each for the most outstanding surgical oncology presentations at the Annual ASiT Conference and the SCTS Annual Meetings.

To promote collaborative work, BASO Trainees has joined forces with Dukes Club and Roux Club, and recently collaborated with BONUS to engage with medical students interested in pursuing surgical oncology.

European Society of Surgical Oncology

BASO maintains a strong relationship with its European sister society ESSO. As per the MoU agreed between both the Societies, BASO members have the privilege to enjoy the full standard membership benefits offered by ESSO including reduced registration rates to the ESSO Annual conference, courses and training programmes. Additionally, BASO members also get the opportunity to apply to an international career development programme, and access to the membership restricted areas on the ESSO website. BASO individuals will now have the voting right at the ESSO General Assembly.

National Clinical Guidelines

BASO maintains a strong presence when National Clinical Guidelines are either developed or updated. BASO Trustees are appointed as the Specialist Advisors for the NICE's Interventional Procedure Programmes. Furthermore, BASO Trustees have been contributing to numerous consultations, and are active members of the different Cancer Commissioning Groups.

All-Party Parliamentary Group on Cancer

BASO Council is pleased to announce its representation as a stakeholder in the All-Party Parliamentary Group on Cancer. BASO is the only organisation representing the surgical community at this group and the BASO Council is confident that this offers BASO a strong position to discuss with policymakers and lobby for the benefit of oncology surgeons.

Health and Social Care Committee Cancer Services Expert Panel

BASO Trustees represented at the roundtable meeting to share views on a number of pledges that government has made to improve cancer services in England. It was a productive meeting and helped voice BASO's concerns, and raised the Society's profile and engagement.

BASO@ UK Oncology Forum

BASO maintains an ongoing collaboration with the UK Oncology Forum and delivers a pan-tumour session every year. This national clinically focussed meeting is open to UK Cancer HCPs and is free for BASO members to attend. The meeting is focused on oncologists and offers BASO a strong presence. BASO Council aims to develop this collaboration further.

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2023

BASO@ Oncology Professional Care

Following the success of last year's collaboration, this year, BASO partnered with the OPC23, and delivered afternoon sessions at the meeting held at London ExCel, and facilitated four sessions on each day. The meeting is designed for Clinical Nurse Specialists, Oncology Nurse Leads, Cancer Researchers, Staff Grade Doctors, Palliative Medicine Consultants, Cancer Pharmacists, and Radiographers etc.

The meeting was a resounding success, boasting an impressive attendance of approx. 1600 delegates, with 619 participating in eight BASO sessions. Notably, this meeting was generously sponsored by the industry partners, rendering it free for BASO members and non-members, while also being CPD accredited.

Under the term of our partnership, BASO received a flat fee of £7500 and secured representation on the programme board. Encouraged by the success of this meeting, BASO Council is actively exploring opportunities for continued and expanded partnership for 2024.

Cancer Services Committee

BASO chaired the RCSENG's Cancer Services Committee (CSC) over a period of time. The CSC has representatives from all surgical disciplines and has served as a focus to communicate the views of surgery as a whole on issues of cancer care. It is the view of the Committee that this forum provides an environment where Surgical Oncology is able to develop a united voice on major issues. The Committee had representations from various surgical societies, Royal Colleges, patient liaison group and Macmillan and acted as a platform to voice the concerns of the cancer services.

However, the CSC is suspended since May 2022, pending a review by the College to assess its functionality and objectives.

BASO Publications

This year, BASO joined ITN business for the World Cancer Day for 'working together: to tackle cancer' campaign. The programme collaborated with various organisations and showcased the scientific advances in treatment, raised awareness of subjects concerning people living with cancer and highlighted how early diagnosis and a collaborative approach are key to a better future for patient outcomes. Click here to watch BASO interview: <https://workingtogether.itn.co.uk/>

BASO Endorsed Meetings

This year, BASO endorsed the following events and meetings:

- BASO/ESSO webinars: 'Controversies on Rectal Cancer Management' - July 2022
- BASO Poster/Oral Prize @ the BONUS Conference – May 2023
- Surgical Oncology in Emergency Setting – September 2023
- 7th Portsmouth Colorectal Congress – May 2023
- BASO/ESSO webinar: 'The Evolving Concept of Neoadjuvant Therapy and Advanced Surgery for Pancreatic Cancer' – May 2023

BASO~ACS continues to support and promote the development of cancer treatment, research, patient care, and education and training of our future generation of oncologists.

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2023

Financial Review

Membership

Membership of the Association has remained steady throughout the year. In response to the recent increase in operational costs due to inflation rates, a nominal increase was unanimously agreed upon for all subscription categories at 2022 AGM. This adjustment ensures that we can effectively cover the rising functional expenses.

As agreed at the 2017 AGM, BASO extends a 50% discounted fee on Full Membership of the BASO~ACS for a period of two years to a BASO Trainees member who have completed their training. This benefit is available to those who have maintained continuous membership in the Society for two consecutive years as paying members.

EJSO

The profits from the EJSO are offset against the cost of the membership subscriptions to the EJSO and these are included in the final reconciliation. A new Journal Publishing agreement between ESSO and BASO as owners, and Elsevier as publishers of the Journal, was made as of 9th December 2020. Elsevier paid a one-off signing bonus of £50,000 to both the Societies that was split 50:50 between BASO and ESSO.

This new agreement with added benefits and revenues for both the Societies began on 1st January 2021 and shall conclude on 31st December 2027. All the parties agreed to meet between Sep-Dec 2024 to review the performance of the Journal in light of expectations and overall market conditions. The updated agreement and the EJSO progression will secure the future income stream for BASO.

The Journal has generated a healthy profit for BASO~ACS in 2022 with an income of £98,634 after the deduction of BASO's membership subscription for the year. It is hoped that the EJSO will continue to grow under the editorship of Professor Riccardo A Audisio.

BASO Grants and Prizes

1. BASO/Rosetrees Research Grants in Cancer surgery 2022 is awarded to:

- **Miss Bhamini Wadhwa** - *Assessment of the fungal mycobiome and its volatile organic signature for earlier detection of oesophagogastric cancer*
- **Mr Jayan George** - *Assessing frailty and its impacts on older patients facing bowel cancer surgery*

2. Ronald Raven Travelling Fellowship Grant of £3,000 in total was awarded to:

- **Michael Boland**, Consultant Oncoplastic Breast Surgeon, Imperial Healthcare Trust, London
- **Trevor Yeung**, Fellow in Colorectal Surgery, Peter MacCallum Cancer Centre, Australia

3. BASO Trainees Prize were awarded at the following external meetings:

- SCTS Annual Scientific Meeting
- ASiT Annual Conference
- BONUS Annual Meeting

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2023

[BASO Annual Meeting 2022](#)

BASO Trustees strongly feel that the Charity's continues fulfilling its objective by promoting and sponsoring advancement in research and education of surgical oncology through another successful meeting.

The meeting was supported by industry sponsorship, however, due to higher logistic charges as applicable for London based meetings, the 2022 Annual Conference incurred a loss. This loss was planned and allowed for in the accounts as the National Committee made the decision to fully sponsor the trainees meeting and offering subsidised registration to juniors. It was felt that a successful meeting was needed to fulfil our charitable aims and that a successful meeting would lead to increased membership of the Society.

The conference raised the Association's presence in the field of Cancer research and has helped engage with various organisations and groups; and offered a great networking platform for the BASO members; recruiting new members. The Association maintains a strong level of reserves and has acquired a new income stream with the EJSO; we can continue to invest our reserves in the promotion of education, training and research via our Annual Conferences. However, we do hope to move towards a cost-neutral financial structure.

Structure, Governance and Management

On 1st July 2010 a transfer was made from the unincorporated charity, BASO ~ The Association for Cancer Surgery, to the company limited by guarantee of the same name (Company number: 7225131, Limited by Guarantee and Registered as Charity No 1136067). The company was incorporated on the 15th April 2010 when new Articles were established. Simultaneous transfers were made to the new Association of Breast Surgery, which is also a company limited by guarantee (Company No 7207053 and Registered as Charity 1135699). The two Associations are thus legally independent of each other, with a service agreement between the two Associations to allow for the provision of a shared office and administration. Whilst the degree of separation has increased over time to allow both Associations to evolve and develop their individual identities, they share many goals and continue to work cooperatively together.

In May 2020 both the Associations separated their joint database and IT services, and agreed to retain historic records of joint members or those members of ABS who have attended BASO events and vice versa. The service agreement is subject to periodic review to ensure its continuing relevance and fairness to both Associations. No further substantive changes are envisaged at this stage.

The Ordinary Members of the BASO~ACS National Committee and the Honorary Officer position of Vice President (who are also Trustees and Directors) are elected by a ballot of the Membership of the Association, following a 'Call for Nominations'. Officer posts (bar the Vice President position) are notified to the Membership by a call for nominations, followed by a ballot of Trustees if there is more than one candidate. All Honorary Officers are also Trustees and Directors. All appointments are confirmed by the Membership at the AGM.

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2023

BASO~ACS has National Committee meetings four times a year. The main business of BASO~ACS is decided upon at its National Committee meetings. Decisions in-between times are made by phone or e-mail communication between the Honorary Officers, with day-to-day issues being dealt with by the Association Manager in liaison with the Honorary Officers. The Trustees/Directors regularly review the major risks that the charity faces and its reserve policy, combined with an annual internal audit of the controls over key financial systems, which are designed to provide sufficient resources in the event of adverse conditions. No major risks have been identified by the Trustees during the year.

The Trustees pay due regard to the Charity Commission's guidance on public benefit when deciding what activities the Charity should undertake.

Reserves Policy

BASO ~ ACS holds a sufficient reserve to allow the society to meet financial obligations in the event of a financial loss following an annual conference, to maintain the low level of conference fees for delegates and to obviate the need for increases in Membership fees. Free reserves held at the year end, being unrestricted funds not represented by fixed assets, totalled £254,096. The level of reserves, and income from conferences and subscriptions, is crucial to the Association's work and objectives, and is monitored carefully to ensure a balance between a secure financial position for the Association and minimal costs to Members and potential Members.

Investment Policy

The Trustees have power under the Articles to invest funds in the same manner and subject to the same conditions as the Trustees of a trust are permitted to do by the Trustee Act 2000. The Association currently holds its reserves across three deposit accounts: BASO ~ ACS holds reserves in a Scottish Widows 90-day notice account; an instant access account with Lloyds TSB; and a further instant access account with Virgin Money. BASO Trustees are looking into new investment opportunities for the Association's reserves.

Plans for the Future

Growth of the core membership and the breadth of specialisms represented were set out as key aims for 2022-23. Whilst overall growth has not materialised, membership numbers have remained steady and the Trustees are actively seeking stronger links with other Associations, many of whom have been invited to nominate observers to Council meetings and to whose meetings we have offered to send observers, with the intention of improving communication and understanding in areas of common interest. Several of these Associations have expressed an interest and the Trustees look forward to reporting on progress in this area in future. The present Trustees themselves represent a broad cross-section of specialisms and so bring a welcome breadth of experience and perspective to the steering process.

BASO Trustees intend to establish affiliation support for smaller complex cancer surgical groups, offering them affiliation to BASO membership and endorsement of their meeting, etc., thereby expanding the Association's distinctive "brand" as the umbrella Society for all Cancer Surgeons.

To this end, in 2010-23 the Association has made significant contribution to different consultations as organised by NICE. The Trustees are actively developing collaborations with different Royal Colleges, Cancer Commissioning Boards/Reference Groups, Public Health England, GMC and many other interested parties with the aim – as always - of sharing knowledge, opening out debate and improving best practice for the benefit of cancer patients.

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2023

BASO Trustees have joined the Specialised Cancer Clinical Commissioning Group and using its wealth of experts are supporting service development in cancer surgery.

BASO will continue to fund research grants in partnership with Rosetrees Trust to support surgical oncology research. This initiative will foster increasing the breadth of surgical research, and the shortlisted studies will be suitable for inclusion in the NIHR portfolio studies.

BASO will extend its sponsorship and support to regional level meetings, and Student Surgical Societies.

BASO Trainees membership is now open to Medical Students and Foundation Year Trainees, those interested in surgical oncology, with the aim to support their training and further education & career in cancer surgery.

As training and work pressures change with an ever-evolving healthcare service, our BASO Trainees group intends to improve the experience, training, and professional competence of surgical trainees with an interest in oncology, principally in academic and research matters.

This report has been prepared having taken advantage of the small companies exemption in the Companies Act 2006.

Approved by the Trustees on 6 November 2023 and signed on their behalf by:

Michael Shackcloth

.....
Mr Michael Shackcloth

Honorary Treasurer

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES

YEAR ENDED 30 JUNE 2023

I report to the charity trustees on my examination of the accounts of the company for the year ended 30 June 2023 which are set out on pages 13 to 20.

Responsibilities and basis of report

As the charity trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Colin Barker

.....
C A Barker FCA

Edmund Carr LLP
146 New London Road
Chelmsford
CM2 0AW

16 November 2023

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

**STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND
EXPENDITURE ACCOUNT)**

YEAR ENDED 30 JUNE 2023

		Unrestricted Funds	Restricted Funds	Total Funds 2023	Total Funds 2022
	Note	£	£	£	£
INCOME from:					
Charitable activities:					
Members' subscriptions		34,442	-	34,442	33,949
BASO Conference and Meetings	2	38,445	-	38,445	18,670
Publications - EJSO		111,143	-	111,143	80,270
Other trading activities		-	-	-	10
Investments	3	728	769	1,497	181
TOTAL INCOME		<u>184,758</u>	<u>769</u>	<u>185,527</u>	<u>133,080</u>
EXPENDITURE on:					
Charitable activities					
Subscriptions - ESSO		9,165	-	9,165	7,464
BASO Conference and Meetings	2	65,896	-	65,896	10,184
Publications - EJSO		12,509	-	12,509	10,781
Fellowships & awards	4	28,027	4,000	32,027	14,669
National Committee and support costs	5	95,296	-	95,296	68,045
TOTAL EXPENDITURE		<u>210,893</u>	<u>4,000</u>	<u>214,893</u>	<u>111,143</u>
NET INCOME/(EXPENDITURE)		(26,135)	(3,231)	(29,366)	21,937
Transfers between funds		-	-	-	-
NET MOVEMENT IN FUNDS		(26,135)	(3,231)	(29,366)	21,937
RECONCILIATION OF FUNDS					
Total funds brought forward		280,620	29,504	310,124	288,187
Total funds carried forward		<u>254,485</u>	<u>26,273</u>	<u>280,758</u>	<u>310,124</u>

The charity has no recognised gains or losses other than the results for the period as set out above.

The notes on pages 15 to 20 form part of these financial statements.

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
BALANCE SHEET
AS AT 30 JUNE 2023**

		2023		2022	
	Note	£	£	£	£
FIXED ASSETS					
Tangible assets	10		389		566
CURRENT ASSETS					
Debtors	11	10,685		19,122	
Cash at bank		356,089		362,103	
		<u>366,774</u>		<u>381,225</u>	
CREDITORS: Amounts falling due within one year	12	<u>(86,405)</u>		<u>(71,667)</u>	
NET CURRENT ASSETS			280,369		309,558
TOTAL ASSETS LESS CURRENT LIABILITIES			<u>280,758</u>		<u>310,124</u>
NET ASSETS			<u>280,758</u>		<u>310,124</u>
FUNDS					
Unrestricted	13		254,485		280,620
Restricted	14		26,273		29,504
TOTAL FUNDS			<u>280,758</u>		<u>310,124</u>

For the year ending 30 June 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006 and with the Financial Reporting Standard (FRS102) (effective 1 January 2019).

These financial statements were approved by the Trustees on 6 November 2023 and are signed on their behalf by:

Zaed Hamady

MR ZAED HAMADY

Michael Shackcloth

MR MICHAEL SHACKCLOTH

Company Registration Number: 7225131

The notes on pages 15 to 20 form part of these financial statements.

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2023

1. ACCOUNTING POLICIES

Basis of accounting

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

BASO - The Association for Cancer Surgery meets the definition of a public benefit entity under FRS102. Assets and Liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes. The financial statements are prepared in sterling, which is the functional currency of the charity, and rounded to the nearest £. The charity is a company limited by guarantee.

Going Concern

The financial statements have been prepared on a going concern basis as the Trustees believe that no material uncertainties exist. The Trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern.

Incoming Resources

Income from conferences held during the year is accounted for on an accruals basis. Membership subscriptions are recognised on receipt.

Resources Expended

All expenditure is accounted for on an accruals basis and includes VAT as the charity is not VAT registered. The majority of costs are attributable to specific charitable activities (ie conferences/awards). Fellowships and awards are accounted for in the period in which they are notified to the recipient. Governance costs are associated with the governance arrangements of the charity. Staff and office costs are recharged to the charity under the service agreement with ABS.

Debtors and creditors

Trade and other debtors are recognised at the settlement amount due. Creditors are recognised at their settlement amount.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and deposits.

Fixed Assets and Depreciation

Fixed assets are shown at historical cost. Expenditure on tangible fixed assets is capitalised. The cost of other items is written off as incurred.

Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:

Computer equipment	25% reducing balance
Fixtures & fittings	25% reducing balance

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2023**

ACCOUNTING POLICIES continued

Fund accounting

Funds held by the charity are either:

Unrestricted general funds – these are funds which can be used in accordance with the charitable objects at the discretion of the trustees.

Restricted funds – these are funds that can only be used for particular restricted purposes within the objects of the charity.

2. CHARITABLE ACTIVITIES

SCIENTIFIC CONFERENCE AND MEETINGS

	Unrestricted Funds	Restricted Funds	Total Funds 2023	Total Funds 2022
Income	£	£	£	£
BASO Conference Fees	28,945	-	28,945	16,670
Lecture grants	2,000	-	2,000	2,000
Other meetings	7,500	-	7,500	-
	<u>38,445</u>	<u>-</u>	<u>38,445</u>	<u>18,670</u>
Expenditure				
BASO Conference	43,013	-	43,013	10,184
BASO 50th Anniversary Meeting	12,456	-	12,456	-
Other meetings	10,427	-	10,427	-
	<u>65,896</u>	<u>-</u>	<u>65,896</u>	<u>10,184</u>

3. INVESTMENT INCOME

All of the charity's investment income arises from interest bearing deposit accounts.

4. FELLOWSHIPS & AWARDS

	Unrestricted Funds	Restricted Funds	Total Funds 2023	Total Funds 2022
	£	£	£	£
Ronald Raven Prize	-	600	600	600
Ronald Raven Travel Scholarships	-	3,000	3,000	3,000
Alan Edwards Memorial Fund	-	400	400	400
BASO/Rosetrees Research Grant	25,000	-	25,000	-
NIHR Project Grants	-	-	-	7,750
Other awards and medals	3,027	-	3,027	2,919
	<u>28,027</u>	<u>4,000</u>	<u>32,027</u>	<u>14,669</u>
2022	10,669	4,000	14,669	

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2023

5. NATIONAL COMMITTEE & SUPPORT COSTS

	Unrestricted Funds	Restricted Funds	Total Funds 2023	Total Funds 2022
	£	£	£	£
Staff salaries and pension costs	53,206	-	53,206	50,111
National committee costs	2,058	-	2,058	1,457
Other support costs	16,352	-	16,352	11,798
Governance costs (note 6)	23,680	-	23,680	4,679
	<u>95,296</u>	<u>-</u>	<u>95,296</u>	<u>68,045</u>
2022	68,045	-	68,045	

6. GOVERNANCE COSTS

	Unrestricted Funds	Restricted Funds	Total Funds 2023	Total Funds 2022
	£	£	£	£
Accounting and payroll services	3,919	-	3,919	3,253
Independent examination fee	620	-	620	590
Fees payable to independent examiner	4,539	-	4,539	3,843
Bank charges	389	-	389	391
Legal and professional fees	18,752	-	18,752	445
	<u>23,680</u>	<u>-</u>	<u>23,680</u>	<u>4,679</u>

7. STAFF COSTS AND EMOLUMENTS

Total staff costs were as follows:	2023	2022
	£	£
Wages & salaries	48,726	46,394
Pension costs (defined contribution scheme)	4,480	3,717
	<u>53,206</u>	<u>50,111</u>

Particulars of employees:

The average number of employees during the year was 1, (full-time equivalent - 0.8)
(2022 - 1 employee and 0.8 FTE)

No employee received remuneration of more than £60,000 during the period.

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2023**

8. NET OUTGOING RESOURCES FOR THE YEAR

	2023	2022
	£	£
This is stated after charging:		
Depreciation	177	138

9. TRUSTEES' REMUNERATION

None of the Trustees were paid any remuneration by the Association during the period.
Trustees are reimbursed reasonable expenses incurred when acting on behalf of the company.
Expenses totalling £848 were reimbursed to 5 trustees during the period (2022 - £760 to 4 Trustees).

10. TANGIBLE FIXED ASSETS

	Computer equipment £	Fixtures & fittings £	Total £
COST			
At 1 July 2022	3,060	2,421	5,481
Additions	-	-	-
Disposals	(369)	(839)	(1,208)
At 30 June 2023	<u>2,691</u>	<u>1,582</u>	<u>4,273</u>
DEPRECIATION			
At 1 July 2022	2,501	2,414	4,915
Charge for the year	170	7	177
Disposals	(369)	(839)	(1,208)
At 30 June 2023	<u>2,302</u>	<u>1,582</u>	<u>3,884</u>
NET BOOK VALUE			
At 30 June 2023	<u>389</u>	<u>-</u>	<u>389</u>
At 30 June 2022	<u>559</u>	<u>7</u>	<u>566</u>

11. DEBTORS

	2023	2022
	£	£
Trade debtors	-	300
Prepayments and Accrued income	10,685	5,706
Other Debtors	-	13,116
	<u>10,685</u>	<u>19,122</u>

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2023

12. CREDITORS: Amounts falling due within one year

	2023	2022
	£	£
Trade creditors	-	482
Accruals	26,317	11,117
Deferred income	60,088	60,068
	<u>86,405</u>	<u>71,667</u>

Deferred income relates to EJSO royalties received in advance for the following period.

13. UNRESTRICTED FUNDS

Current year	Movement in resources:				Balance at 30/06/2023 £
	Balance at 01/07/2022 £	Incoming £	Outgoing £	Transfers £	
General unrestricted funds	<u>280,620</u>	<u>184,758</u>	<u>(210,893)</u>	<u>-</u>	<u>254,485</u>
Prior year	Balance at 01/07/2020 £	Incoming £	Outgoing £	Transfers £	Balance at 30/06/2021 £
General unrestricted funds	<u>254,732</u>	<u>133,031</u>	<u>(107,143)</u>	<u>-</u>	<u>280,620</u>

14. RESTRICTED FUNDS

Current year	Movement in resources:				Balance at 30/06/2023 £
	Balance at 01/07/2022 £	Incoming £	Outgoing £	Transfers £	
a) Alan Edwards Memorial Fund	5,178	153	(400)	-	4,931
b) Ronald Raven Prize Fund	1,876	291	(600)	-	1,567
c) Ronald Raven Travelling Fellowship Fund	22,450	325	(3,000)	-	19,775
	<u>29,504</u>	<u>769</u>	<u>(4,000)</u>	<u>-</u>	<u>26,273</u>

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2023**

14. RESTRICTED FUNDS

<i>Prior year</i>	<i>Movement in resources:</i>				<i>Balance at 30/06/2022</i>
	<i>Balance at 01/07/2021</i>	<i>Incoming</i>	<i>Outgoing</i>	<i>Transfers</i>	
	£	£	£	£	£
a) <i>Alan Edwards Memorial Fund</i>	5,569	9	(400)	-	5,178
b) <i>Ronald Raven Prize Fund</i>	2,469	7	(600)	-	1,876
c) <i>Ronald Raven Travelling Fellowship Fund</i>	25,417	33	(3,000)	-	22,450
	<u>33,455</u>	<u>49</u>	<u>(4,000)</u>	<u>-</u>	<u>29,504</u>

15. ANALYSIS OF NET ASSETS (between restricted and unrestricted funds)

<i>Current year</i>	<i>Tangible fixed assets</i>	<i>Other net assets</i>	<i>Total</i>
	£	£	£
Restricted funds	-	26,273	26,273
Unrestricted funds	389	254,096	254,485
	<u>389</u>	<u>280,369</u>	<u>280,758</u>
<i>Prior year</i>	<i>Tangible fixed assets</i>	<i>Other net assets</i>	<i>Total</i>
	£	£	£
<i>Restricted funds</i>	-	29,504	29,504
<i>Unrestricted funds</i>	566	280,054	280,620
	<u>566</u>	<u>309,558</u>	<u>310,124</u>

16. COMPANY LIMITED BY GUARANTEE

The company is controlled by its members. Every member of the company undertakes to contribute to the assets of the Company in the event of the same being wound up during the time he/she is a member, or within one year afterwards, for the payments of the debts and liabilities of the company contracted before the time at which he/she ceases to be a member and of the costs, charges and expenses of winding up the same, and for the adjustments of the rights of the contributors among themselves such amount as may be required not exceeding one pound.

17. RELATED PARTY TRANSACTIONS

There were no related party transactions that require disclosure during the year other than the reimbursement of expenses to Trustees, disclosed in Note 9.

Accounts

COMPANY REGISTRATION NUMBER : 7225131

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
UNAUDITED FINANCIAL STATEMENTS
FOR
YEAR ENDED 30 JUNE 2022**

Charity Number : 1136067



Edmund Carr LLP
Chartered Accountants
146 New London Road
Chelmsford
Essex
CM2 0AW

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2022

CONTENTS	PAGE
Company information	1
Trustees' annual report	2
Independent Examiner's report to the Trustees	11
Statement of financial activities	12
Balance sheet	13
Notes to the financial statements	14

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

COMPANY INFORMATION

YEAR ENDED 30 JUNE 2022

Charity Number	1136067
Company Number	7225131
Registered Office	38-43 Lincoln's Inn Fields London WC2A 3PE

THE TRUSTEES

The Trustees of the charity are also the directors of the charity.

The Trustees who served the charity during the year were as follows:

Mr Hassan Malik	(Resigned 21/11/2021)	President (to 21/11/2021)
Mr Zaed Hamady		President (from 22/11/2021)
		Vice President (to 21/11/2021)
Professor Michael Douek		Vice President (from 22/11/2021)
		Honorary Secretary (to 21/11/2021)
Mr John Whiting		EJSO Representative (from 22/11/2021)
		Honorary Treasurer (to 21/11/2021)
Mr Michael Shackcloth		Honorary Treasurer (from 22/11/2021)
		EJSO Representative (to 21/11/2021)
Mr Anant Desai		Honorary Secretary (from 22/11/2021)
Professor Jim Khan		Meeting Secretary
Mr Avi Agrawal	(Appointed 21/11/2021)	
Mr Edmund Leung		
Professor Derek Manas		
Mr Aaron Quyn		
Professor Richard Shaw	(Resigned 21/11/2021)	
Mr Paul Skaife	(Appointed 21/11/2021)	
Professor Jayant Vaidya		

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT
YEAR ENDED 30 JUNE 2022**

The Trustees have pleasure in presenting their report and the unaudited financial statements for the charity for the year ended 30th June 2022. The Trustees of the charity as shown on page 1 are also the directors of the charity.

Objectives and Activities

The Charity's objectives are:

To advance the science, practice, and art of surgical oncology for the benefit of patients with cancer; and to *promote research, training, and education in surgical oncology* for the benefit of the public, patients and the medical community, and to disseminate the useful results of that research appropriately.

The Association seeks to act as an umbrella organisation for those working in all surgical cancer specialties and cancer research. In addition, the Society focuses on innovation in cancer care and support for future workforce training and development. The Trustees pay due regard to the Charity Commission's guidance on public benefit when deciding what activities the Charity should undertake.

Portfolio of BASO Prizes and Awards

The Association takes great pride in its **portfolio of awards** to encourage our junior colleagues and to support their interest in the field of surgical oncology, its research and care of cancer patients. Follow link for more details: <https://baso.org.uk/education-training.aspx>. The Society continues awarding the following prizes at its annual scientific meeting:

- **Alan Edwards Memorial Prize** is awarded to the best poster presentation.
- **Ronald Raven Presentation Prize** is awarded to the best oral paper presentation.
- **BASO~ACS Presentation Prize**, formerly known as BJS Prize, is awarded to the best oral paper presentation. Due to the change of structure, the British Journal of Surgery Society (BJSS) discontinued to support this prize. In 2019, BASO Council agreed to sponsor this prize to ensure continuity to the BJS Paper Presentation Prize awarded at the BASO Meeting.
- **BASO Trainees (poster/oral presentation) Prize** is awarded to the best poster and oral paper presentations at the BASO Trainees Meeting.

To expand its commitment to all cancer-related professionals, BASO announced the following new prizes:

- **BASO Trainees Audit/QIP Prize** to support and encourage trainees, those involved with audit and quality improvement with a view of improving care to patients, in particular, cancer patients.
- **BASO Multidisciplinary Prize** to recognise the work done by our Non-Medical Professional colleagues in supporting cancer patients. This unique award is designed to highlight any research, audit, quality improvement, health service provision/development, cancer patient pathway study, cancer survivorship study.
- **BASO Medical Student Prize** to support and encourage medical students with an interest in surgical oncology.

Each year, to support and encourage trainees interest in the field of surgical oncology, BASO offers an array of prizes for the best surgical oncology presentation by a trainee at the annual scientific conference of the ASGBI, ASiT, SCTS and of each of the Surgical Specialty Associations.

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2022

Over the years, BASO has developed a prestigious portfolio of Awards presented to surgeons and trainees in recognition of their outstanding achievement and contribution to the cancer surgery; its research and education.

In addition to **Ronald Raven Lifetime Achievement Award**, **Geoff Oats Award** and **Uccio Querci della Rovere Award**, this year BASO inaugurated - **BASO Medal for Excellence** to mark the 50th Anniversary of the founding of the Association, the BASO Council inaugurates the British Association of Surgical Oncology Medal for Excellence to recognise the role of individual surgeon or teams in the advancement of cancer care. This award is inaugurated at the 2021 BASO Annual Scientific Conference and will be presented to a professional or a team in recognition of their outstanding achievements in the field of cancer surgery: excellence in research, clinical practice, education and innovation. This international award will be presented on a 5 year basis and will be open to all members and non-members of the Association for their contribution to UK cancer surgery. BASO is honoured have presented the very first award to Professor Freddie Hamdy. Follow link for more details: <https://baso.org.uk/baso~acs-conferences/baso-50th-anniversary-meeting.aspx>

BASO Grants

BASO is expanding its portfolio of research grants to support research. Follow link for more details: <https://baso.org.uk/education-training.aspx>

BASO Raven Travelling Fellowship - (formerly known as Ronald Raven Travelling Fellowship) was endowed in 1993 by the Ronald Raven Trustees in memory of Ronald W. Raven, the Founder of the Association. BASO Continues to fund and award this fellowship, which has now increased to £3,000, each year to aspiring trainees to support them to expand their skills and experience in the surgical cancer treatment.

BASO (NIHR) Research Project Grant - BASO continues to be a non-commercial partner with the National Institute of Health Research (NIHR) and delivered a successful annual research project grant scheme to assist surgeons in undertaking research projects related to surgically linked cancer care. This grant was open for discrete projects and a study awarded this grant is automatically eligible for consideration for the Clinical Research Network Support, thereby, is considered for being a portfolio study. In 2021, BASO has announced a new Research Grant in Cancer Surgery, in partnership with the Rosetrees Trust, that will replace the BASO (NIHR) Research Project Grants from 2022 onwards.

BASO/Rosetrees Research Grants in Cancer Surgery - In celebration of BASO's 50 years, BASO National Committee announced a new research grants in cancer surgery in partnership with the Rosetrees Trust. The research grants are for up to £50,000 over 3 years and will be match funded by Rosetrees Trust. The first round of the grants were awarded at BASO's 50th Anniversary Celebration meeting. Successful applications will be eligible for inclusion in the NIHR portfolio and are encouraged to gain support from a Royal College of Surgeons of England Surgical Interventional Trials Unit (SITU).

Endorsement of Regional Events

The Association aspires to engage with oncologists and Societies on the regional level. Via its network of Regional Representatives, BASO had been supporting various regional and national meetings. However, the participation has been limited during this accounting year due to the post pandemic challenges.

Engagement with Medical Students

In the spirit of encouraging the future generation of surgical oncologists, the Association has opened its Trainees membership to Foundation Year Trainees and Medical Students those wishing to pursue surgical oncology. BASO aims to offer support with their surgical career by providing skills courses, mentoring sessions, and guiding surgical portfolio via our wealth of regional representatives.

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)
YEAR ENDED 30 JUNE 2022**

The Society is actively engaging with undergraduate Medical Societies by sponsoring their annual meeting with BASO Prize and sponsored lectures.

BASO Trainees Group

BASO Trainees group continued growing their outlook and strengthened their links with trainees groups from across Europe. Through these collaborations, we encouraged trainees in tenets of research and clinical excellence in surgical oncology through the sponsored prizes at national specialty meetings. Our Trainees group continues to focus on research, academic training, and fellowships.

BASO's contribution to NICE consultations and Cancer CRGs

The Society continues to make its mark and offers expert advice on numerous site-specific Surgical Cancer consultations as requested by NICE. Our Council members sit on various Cancer CRG's, offering expert advice.

Overall, the Society is maintaining healthy relations with all the surgical societies, the Royal Colleges, and exploring collaborative working opportunities.

Achievements and Performance

The Society continues to support the training and educational needs of our colleagues and address the challenges faced post pandemic. BASO has demonstrated the need for an umbrella organisation to speak with one voice, and is growing its membership, maintained steady finances and delivered another successful virtual meeting this year.

Zenith Global Health Award 2021

BASO is honoured to have been presented the 2021 Zenith Global Health Award in recognition for the Society's contribution to the clinical education and research.

COVID –19

BASO continued to support the CovidSurg-Cancer Study and is one of the key sponsors of this study. CovidSurg-Cancer is an international cohort study, designed by the team in Birmingham to assess the safety of surgery for all types of cancer during COVID-19 pandemic and the impact of pandemic in cancer delay and treatment pathways. BASO, as the non-commercial NIHR partner, is one of the Societies that offers a small surgical research grant to this study which would entitle it to be listed on the NIHR Portfolio.

Our Trustees hope to continue providing support to our members and cancer community to get through the post-pandemic pressures and challenges.

BASO Annual Meeting

To support the ongoing education needs of its members and surgical community, BASO delivered its second virtual Annual Meeting. The meeting was themed on "Innovation in cancer surgery" and was delivered under the leadership of our immediate Past-President Mr Hassan Malik, and Professor Jim Khan, Meeting Secretary.

Conference was delivered via the BASO's (first virtual) event app boosting the engagement and network opportunities. Meeting was facilitated by an array of international speakers and panellists, all esteemed surgeons in the field of surgical oncology and had an attendance of 283 delegates. The feedback received from delegates and speakers was extremely positive, both about the content of the programme and the virtual organisation.

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2022

100 abstracts were presented under oral or poster presentation sessions, and 9 prizes were awarded for best abstract presentations. The meeting also saw several prestigious eponymous lifetime achievement awards and orations given to some of the leading surgeons of our times. Meeting recruited 33 new members and generated a small profit.

The program was packed with some stellar speakers and exciting sessions, hot debates, specialty updates, in conversation with and latest news on surgical education from around the world. The key highlights of the programme were:

- Virtual presentations of oral and poster abstracts presentations.
- Launched new prize session for Medical Students.
- Live Q&A opportunities for delegates and panels.
- BASO Trainees/Skills Day is focused on the themes of simulation, innovation and artificial intelligence.
- Robotics feature big time in the conference program with focus on training, resources and fellowships.
- This year's meeting saw the BASO Raven Lifetime Award to Professor Robert Mansel, Geoff Oates Award to Professor Robert Steele and Uccio Querci della Rovere Award to Professor Jiong Wu.
- Key note lecture by Professor Marescaux on Innovations and developments in cancer surgery and the round table discussion on the future of cancer surgery in view of emerging technologies.
- Medico-legal issues in Covid times, presented an engaging presentation by Mr Robert Wheeler and Professor Peter Sagar.
- Live Q&A opportunities for delegates and panels.

The Association aspires to continue building on the success of this programme and making BASO meetings financially sustainable.

European Journal of Surgical Oncology

The **EJSO**, co-owned by BASO and the ESSO continues to go from strength to strength with a rise in the quality of submission and article downloads. The 2021 impact factor were released earlier in June. The EJSO impact factor has increased to 4.533 from 4.424 from last year. (Follow link for more details: https://journalinsights.elsevier.com/journals/0748-7983/impact_factor_5_year). This is a remarkable jump in citations and credit must be given to the editorial team led by our past President Professor Riccardo Audisio (Editor in Chief).

Network and links with other organisations

The Association continues to grow and strengthen its links with other specialties and to re-establish itself as the umbrella organisation for cancer surgeons, including forming membership links with other specialties, providing consultations, and setting up partnerships for joint conferences in future.

Our **BASO Trainees Group** is also proactively expanding its partnership opportunities and has representation on the ASiT Council. BASO Trainees maintains a portfolio of Trainees Prizes of £100 each for the best surgical oncology presentations at the Annual ASiT Conference, and SCTS Annual Meeting held this year.

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2022

This year, to promote collaborative work, BASO Trainees joined forces with Dukes Club and Roux Club to deliver a joint meeting on 'Essentials of Surgical Research' focused on surgical trainees at the early stage of research pathway. It was a successful event facilitated by expert speakers.

European Society of Surgical Oncology

BASO had signed a 'memorandum-of-understanding' with our European sister society **ESSO** to strengthen the affiliation between the two societies. BASO members did get affiliate membership to ESSO, however, with the updated agreement, BASO members now enjoy standard membership benefits of ESSO including reduced registration rates to the ESSO Annual conference, courses and training programmes. BASO members also get the opportunity to apply to an international career development programme and access to the membership restricted areas to the ESSO website. BASO individuals will now have the voting right at the ESSO General Assembly.

NIHR's Clinical Research Network

The Association also maintains its relationship with the NIHR's Clinical Research Network, and supports the 'Tomorrow's Leaders' programme which enrolls the future leaders in the field of surgical oncology and research. These leaders are encouraged to join our trainees' membership and are offered support to enhance their career in surgical oncology via short workshops, methodology training, research grant, etc.

National Clinical Guidelines

BASO continues to maintain a strong presence when National Clinical Guidelines are either developed or updated. BASO Trustees are appointed as the Specialist Advisors for the NICE's Interventional Procedure Programmes. Furthermore, BASO Trustees have been contributing to numerous consultations, and are active members of the different Cancer Commissioning Groups.

All-Party Parliamentary Group on Cancer

BASO Council is pleased to announce its representation as a stakeholder in the All-Party Parliamentary Group on Cancer. BASO Council is confident that this offers BASO a strong position to discuss with policymakers and lobby for the benefit of oncology surgeons.

Health and Social Care Committee Cancer Services Expert Panel

BASO Trustees represented at the roundtable meeting to share views on a number of pledges that government has made to improve cancer services in England. It was a productive meeting and helped voice BASO's concerns, and raised the Society's profile and engagement.

BASO@ UK Oncology Forum

BASO maintains an ongoing collaboration with the UK Oncology Forum and delivers a pan-tumour session every year. This national clinically focussed meeting is open to UK Cancer HCPs and is free for BASO members to attend. The meeting is focused on oncologists and offers BASO a strong presence. BASO Council aims to develop this collaboration further.

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2022

BASO@ Oncology Professional Care

This year, BASO collaborated with the OPC22, a two-day meeting held at London ExCel, and facilitated five sessions. The meeting is designed for Clinical Nurse Specialists, Oncology Nurse Leads, Cancer Researchers, Staff Grade Doctors, Palliative Medicine Consultants, Cancer Pharmacists, and Radiographers etc.

The meeting was a success and had an attendance of 1300 delegates. The meeting is heavily sponsored by the industry and so was free for BASO members and non-members and was CPD accredited. BASO Council intends to develop a continued partnership based on the success of this meeting.

Cancer Services Committee

BASO~ACS continues chairing the RCSENG's **Cancer Services Committee**, and is now invited to offer expert advice towards the 'Future of Surgery' Commission, and has contributed on 'Restructuring of the MDTs', and GMC's proposal on Draft Credentialing Frame Work. As a surgical oncology society, we are actively engaged in decision making with organisations such as NICE, NCEPOD, Specialist Cancer CRG, the Royal College of Surgeons, and GMC.

BASO Publications

In addition, this accounting year, BASO also engaged with and contributed to:

- In December 2021, BASO worked with Health Awareness on the 2021 Innovations in Oncology campaign and produced an article on '**Protected: Liver transplantation: A new treatment for unresectable liver metastases**'. This article was prepared by Professor Derek Manas, BASO Trustee and Dr Afsana Elanko, Director of Education.
- In October 2021, BASO contributed with the article '***Finding New Methods of Bowel Cancer Screening***' on Health Awareness on the 2021 Innovations in Oncology campaign. The article was prepared by Mr Edmund Leung, BASO Trustee and Dr Afsana Elanko, Director of Education.

BASO Endorsed Meetings

This year, BASO endorsed the following events and meetings:

- Colorectal FRCS viva practice webinar: 2nd July 2021
- ESSO HPB course: 8-10 Nov 2021
- Essentials of Surgical Research: 20th May 2022
- Portsmouth Colorectal Congress (6th Edition): 15-18 June 2022
- Joint ESSO/BASO Webinar – Controversies in rectal cancer management – Consultant's corner: 16th July 2022
- TUGS HPB WEBINARS: Hilar Cholangiocarcinoma & Biliary Strictures

BASO~ACS continues to support and promote the development of cancer treatment, research, patient care, and education and training of our future generation of oncologists.

Financial Review

Membership

Membership of the Association remains stable during the course of the year. Membership subscriptions for 2021-22 continued to be kept intentionally low at £180 for full membership as the Association still holds high levels of reserves.

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2022

The subscription for the BASO Trainees for 2021-22 was also unchanged. As agreed at the 2017 AGM, BASO offers a 50% discounted fee to the Full Membership of the BASO~ACS for two years to a BASO Trainee member upon completion of training, provided they were the paying member of the Society for two consecutive years.

EJSO

The profits from the EJSO are offset against the cost of the membership subscriptions to the EJSO and these are included in the final reconciliation. A new Journal Publishing agreement between EJSO and BASO as owners, and Elsevier as publishers of the Journal, was made as of 9th December 2020. Elsevier paid a one-off signing bonus of £50,000 to both the Societies that was split 50:50 between BASO and EJSO.

This new agreement with added benefits and revenues for both the Societies began on 1st January 2021 and shall conclude on 31st December 2027. All the parties agreed to meet between Sep-Dec 2024 to review the performance of the Journal in light of expectations and overall market conditions. The updated agreement and the EJSO progression will secure the future income stream for BASO.

The Journal has generated a healthy profit for BASO~ACS in 2021 with an income of £69,489 after the deduction of BASO's membership subscription for the year. It is hoped that the EJSO will continue to grow under the editorship of Professor Riccardo A Audisio.

BASO Grants and Prizes

1. **BASO (NIHR) Research Project Grant** The 2021 BASO NIHR Research Project Grant of £5,750 was awarded in support of your project "*Augmentation of Volatile Organic Compounds of Oesophageal Adenocarcinoma from the Tumour Lipidome (the AVOCADO study).*"
2. **Ronald Raven Travelling Fellowship Grant of £3,000 in total** was awarded to:
 - **Mark Wilkie**, (TiG) Fellow in Head & Neck Surgical Oncology, Manchester Royal Infirmary
 - **Nick Eastley**, ST8 Trauma & Orthopaedics, East Midlands (South)
3. **BASO Trainees Prize** were awarded at the following external meetings:
 - SCTS Annual Scientific Meeting
 - ASiT Annual Conference

BASO Annual Meeting 2021

BASO Trustees strongly feel that the Charity's continues fulfilling its objective by promoting and sponsoring advancement in research and education of surgical oncology through another successful meeting.

The meeting was supported by industry sponsorship and had relatively lower costs. Overall the meeting generated a small profit.

The conference raised the Association's presence in the field of Cancer research and has helped engage with various organisations and groups; and offered a great networking platform for the BASO members; recruiting new members. The Association maintains a strong level of reserves and has acquired a new income stream with the EJSO; we can continue to invest our reserves in the promotion of education, training and research via our Annual Conferences. However, we do hope to move towards a cost-neutral financial structure.

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2022

Structure, Governance and Management

On 1st July 2010 a transfer was made from the unincorporated charity, BASO ~ The Association for Cancer Surgery, to the company limited by guarantee of the same name (Company number: 7225131, Limited by Guarantee and Registered as Charity No 1136067). The company was incorporated on the 15th April 2010 when new Articles were established. Simultaneous transfers were made to the new Association of Breast Surgery, which is also a company limited by guarantee (Company No 7207053 and Registered as Charity 1135699). The two Associations are thus legally independent of each other, with a service agreement between the two Associations to allow for the provision of a shared office and administration. Whilst the degree of separation has increased over time to allow both Associations to evolve and develop their individual identities, they share many goals and continue to work co-operatively together.

In May 2020 both the Associations separated their joint database and IT services, and agreed to retain historic records of joint members or those members of ABS who have attended BASO events and vice-versa. The service agreement is subject to periodic review to ensure its continuing relevance and fairness to both Associations. No further substantive changes are envisaged at this stage.

The Ordinary Members of the BASO~ACS National Committee (who are also Trustees and Directors) are elected by a ballot of the Membership of the Association, following a 'Call for Nominations'. Officer posts are notified to the Membership by a call for nominations, followed by a ballot of Trustees if there is more than one candidate. All Honorary Officers are also Trustees and Directors. All appointments are confirmed by the Membership at the AGM. BASO~ACS has National Committee meetings four times a year.

BASO also administer the Royal College of Surgeons of England's Cancer Services Committee, which meets three times a year and is chaired by the President of BASO~ACS. The main business of BASO~ACS is decided upon at its National Committee meetings. Decisions in-between times are made by phone or e-mail communication between the Honorary Officers, with day-to-day issues being dealt with by the Association Manager in liaison with the Honorary Officers. The Trustees/Directors regularly review the major risks that the charity faces and its reserve policy, combined with an annual internal audit of the controls over key financial systems, which are designed to provide sufficient resources in the event of adverse conditions. No major risks have been identified by the Trustees during the year.

The Trustees pay due regard to the Charity Commission's guidance on public benefit when deciding what activities the Charity should undertake.

Reserves Policy

BASO ~ ACS holds a sufficient reserve to allow the society to meet financial obligations in the event of a financial loss following an annual conference, to maintain the low level of conference fees for delegates and to obviate the need for increases in Membership fees. The level of reserves, and income from conferences and subscriptions, is crucial to the Association's work and objectives, and is monitored carefully to ensure a balance between a secure financial position for the Association and minimal costs to Members and potential Members.

Investment Policy

The Trustees have power under the Articles to invest funds in the same manner and subject to the same conditions as the Trustees of a trust are permitted to do by the Trustee Act 2000. The Association currently holds its reserves across three deposit accounts: BASO ~ ACS holds reserves in a Scottish Widows 90-day notice account; an instant access account with Lloyds TSB; and a further instant access account with Virgin Money. BASO Trustees are looking into new investment opportunities for the Association's reserves.

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2022

Plans for the Future

Growth of the core membership and the breadth of specialisms represented were set out as key aims for 2021-22. Whilst overall growth has not materialised, membership numbers have remained steady and the Trustees are actively seeking stronger links with other Associations, many of whom have been invited to nominate observers to Council meetings and to whose meetings we have offered to send observers, with the intention of improving communication and understanding in areas of common interest. Several of these Associations have expressed an interest and the Trustees look forward to reporting on progress in this area in future. The present Trustees themselves represent a broad cross-section of specialisms and so bring a welcome breadth of experience and perspective to the steering process.

BASO Trustees intend to establish affiliation support for smaller complex cancer surgical groups, offering them affiliation to BASO membership and endorsement of their meeting, etc., thereby expanding the Association's distinctive "brand" as the umbrella Society for all Cancer Surgeons.

To this end, in 2010-22 the Association has made significant contribution to different consultations as organised by NICE. The Trustees are actively developing collaborations with different Royal Colleges, Cancer Commissioning Boards/Reference Groups, Public Health England, GMC and many other interested parties with the aim – as always - of sharing knowledge, opening out debate and improving best practice for the benefit of cancer patients.

The Cancer Services Committee is currently reviewing the issue of 'complex surgical oncology training', 'Fellowship training recommendations for cancer surgery' and 'Cancer Recovery Task Force'. BASO has been invited to contribute to the 'future of surgery' commissioning of the RCS; and the CSC would ideally aspire to have direct representation on the RCS Council. The Cancer Services Committee has also been invited to be involved in setting the quality metrics for cancer surgery for the UK, in conjunction with CRUK and NCIN.

BASO Trustees have joined the Specialised Cancer Clinical Commissioning Group and using its wealth of experts are supporting service development in cancer surgery.

BASO will continue to fund research grants in partnership with Rosetrees Trust to support surgical oncology research. This initiative will foster increasing the breadth of surgical research, and the shortlisted studies will be suitable for inclusion in the NIHR portfolio studies.

BASO will extend its sponsorship and support to regional level meetings, and Student Surgical Societies. BASO Trainees membership is now open to Medical Students and Foundation Year Trainees, those interested in surgical oncology, with the aim to support their training and further education & career in cancer surgery.

As training and work pressures change with an ever-evolving healthcare service, our BASO Trainees group intends to improve the experience, training, and professional competence of surgical trainees with an interest in oncology, principally in academic and research matters.

This report has been prepared having taken advantage of the small companies exemption in the Companies Act 2006.

Approved by the Trustees on 20 November 2022 and signed on their behalf by:

Michael Shackcloth

.....

**Mr Michael Shackcloth
Honorary Treasurer**

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES

YEAR ENDED 30 JUNE 2022

I report to the charity trustees on my examination of the accounts of the company for the year ended 30 June 2022 which are set out on pages 12 to 19.

Responsibilities and basis of report

As the charity trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Colin Barker

C A Barker FCA

Edmund Carr LLP
146 New London Road
Chelmsford
CM2 0AW

23 November 2022

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

**STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND
EXPENDITURE ACCOUNT)**

YEAR ENDED 30 JUNE 2022

		Unrestricted Funds	Restricted Funds	Total Funds 2022	Total Funds 2021
	Note	£	£	£	£
INCOME from:					
Charitable activities:					
Members' subscriptions		33,949	-	33,949	32,836
Scientific conference	2	18,670	-	18,670	4,110
Publications - EJSO		80,270	-	80,270	101,547
Other trading activities		10	-	10	47
Investments	3	132	49	181	199
TOTAL INCOME		<u>133,031</u>	<u>49</u>	<u>133,080</u>	<u>138,739</u>
EXPENDITURE on:					
Charitable activities					
Subscriptions - ESSO		7,464	-	7,464	7,366
Scientific conference	2	10,184	-	10,184	3,188
Publications - EJSO		10,781	-	10,781	11,180
Fellowships & awards	4	10,669	4,000	14,669	4,500
National Committee and support costs	5	68,045	-	68,045	53,331
TOTAL EXPENDITURE		<u>107,143</u>	<u>4,000</u>	<u>111,143</u>	<u>79,565</u>
NET INCOME/(EXPENDITURE)		25,888	(3,951)	21,937	59,174
Transfers between funds		-	-	-	-
NET MOVEMENT IN FUNDS		25,888	(3,951)	-	-
RECONCILIATION OF FUNDS					
Total funds brought forward		254,732	33,455	288,187	229,013
Total funds carried forward		<u>280,620</u>	<u>29,504</u>	<u>310,124</u>	<u>288,187</u>

The charity has no recognised gains or losses other than the results for the period as set out above.

The notes on pages 14 to 19 form part of these financial statements.

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
BALANCE SHEET
AS AT 30 JUNE 2022**

		2022		2021	
	Note	£	£	£	£
FIXED ASSETS					
Tangible assets	10		566		704
CURRENT ASSETS					
Debtors	11	19,122		11,188	
Cash at bank		362,103		340,605	
		<u>381,225</u>		<u>351,793</u>	
CREDITORS: Amounts falling due within one year	12	<u>(71,667)</u>		<u>(64,310)</u>	
NET CURRENT ASSETS			309,558		287,483
TOTAL ASSETS LESS CURRENT LIABILITIES			<u>310,124</u>		<u>288,187</u>
NET ASSETS			<u>310,124</u>		<u>288,187</u>
FUNDS					
Unrestricted	13		280,620		254,732
Restricted	14		29,504		33,455
TOTAL FUNDS			<u>310,124</u>		<u>288,187</u>

For the year ending 30 June 2022 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006 and with the Financial Reporting Standard (FRS102) (effective 1 January 2019).

These financial statements were approved by the Trustees on 20 November 2022 and are signed on their behalf by:

Zaed Hamady
.....

MR ZAED HAMADY

Michael Shackcloth
.....

MR MICHAEL SHACKCLOTH

Company Registration Number: 7225131

The notes on pages 14 to 19 form part of these financial statements.

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2022

1. ACCOUNTING POLICIES

Basis of accounting

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

BASO - The Association for Cancer Surgery meets the definition of a public benefit entity under FRS102. Assets and Liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes. The financial statements are prepared in sterling, which is the functional currency of the charity, and rounded to the nearest £. The charity is a company limited by guarantee.

Going Concern

The financial statements have been prepared on a going concern basis as the Trustees believe that no material uncertainties exist. The Trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern.

Incoming Resources

Income from conferences held during the year is accounted for on an accruals basis. Membership subscriptions are recognised on receipt.

Resources Expended

All expenditure is accounted for on an accruals basis and includes VAT as the charity is not VAT registered. The majority of costs are attributable to specific charitable activities (ie conferences/awards). Fellowships and awards are accounted for in the period in which they are notified to the recipient. Governance costs are associated with the governance arrangements of the charity. Staff and office costs are recharged to the charity under the service agreement with ABS.

Debtors and creditors

Trade and other debtors are recognised at the settlement amount due. Creditors are recognised at their settlement amount.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and deposits.

Fixed Assets and Depreciation

Fixed assets are shown at historical cost. Expenditure on tangible fixed assets is capitalised. The cost of other items is written off as incurred.

Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:

Computer equipment	25% reducing balance
Fixtures & fittings	25% reducing balance

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2022**

ACCOUNTING POLICIES continued

Fund accounting

Funds held by the charity are either:

Unrestricted general funds – these are funds which can be used in accordance with the charitable objects at the discretion of the trustees.

Restricted funds – these are funds that can only be used for particular restricted purposes within the objects of the charity.

**2. CHARITABLE ACTIVITIES
SCIENTIFIC CONFERENCE**

	Unrestricted Funds	Restricted Funds	Total Funds 2022	Total Funds 2021
	£	£	£	£
Income				
Fees	16,670	-	16,670	4,110
Lecture grants	2,000	-	2,000	-
	<u>18,670</u>	<u>-</u>	<u>18,670</u>	<u>4,110</u>
Expenditure				
Speaker expenses	-	-	-	-
Venue and catering costs	-	-	-	-
Other conference costs	10,184	-	10,184	3,188
	<u>10,184</u>	<u>-</u>	<u>10,184</u>	<u>3,188</u>

All conference income and expenditure in 2021 was unrestricted.

3. INVESTMENT INCOME

All of the charity's investment income arises from interest bearing deposit accounts.

4. FELLOWSHIPS & AWARDS

	Unrestricted Funds	Restricted Funds	Total Funds 2022	Total Funds 2021
	£	£	£	£
Ronald Raven Prize	-	600	600	600
Ronald Raven Travel Scholarships	-	3,000	3,000	3,000
Alan Edwards Memorial Fund	-	400	400	400
Other awards and medals	10,669	-	10,669	500
	<u>10,669</u>	<u>4,000</u>	<u>14,669</u>	<u>4,500</u>

In 2021 Other Awards were paid from unrestricted funds. All other prizes were paid from restricted funds.

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2022

5. NATIONAL COMMITTEE & SUPPORT COSTS

	Unrestricted Funds	Restricted Funds	Total Funds 2022	Total Funds 2021
	£	£	£	£
Staff salaries and pension costs	50,111	-	50,111	40,272
National committee costs	1,457	-	1,457	-
Service agreement charges	-	-	-	1,800
Other support costs	11,798	-	11,798	5,344
Governance costs (note 6)	4,679	-	4,679	5,915
	<u>68,045</u>	<u>-</u>	<u>68,045</u>	<u>53,331</u>

All national committee and support costs in 2021 were unrestricted.

6. GOVERNANCE COSTS

	Unrestricted Funds	Restricted Funds	Total Funds 2022	Total Funds 2021
	£	£	£	£
Accounting and payroll services	3,253	-	3,253	4,025
Independent examination fee	590	-	590	575
Fees payable to independent examiner	3,843	-	3,843	4,600
Bank charges	391	-	391	416
Other professional fees	445	-	445	899
	<u>4,679</u>	<u>-</u>	<u>4,679</u>	<u>5,915</u>

7. STAFF COSTS AND EMOLUMENTS

Total staff costs were as follows:

	2022	2021
	£	£
Wages & salaries	46,394	37,072
Pension costs (defined contribution scheme)	3,717	3,200
	<u>50,111</u>	<u>40,272</u>

Particulars of employees:

The average number of employees during the year was 1, (full-time equivalent - 0.8)
(2021 - 1 employee and 0.8 FTE)

No employee received remuneration of more than £60,000 during the period.

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2022**

8. NET OUTGOING RESOURCES FOR THE YEAR

	2022	2021
	£	£
This is stated after charging:		
Depreciation	138	168

9. TRUSTEES' REMUNERATION

None of the Trustees were paid any remuneration by the Association during the period.
Trustees are reimbursed reasonable expenses incurred when acting on behalf of the company.
Expenses totalling £760 were reimbursed to 4 trustees during the period (2021 - £188 to 1 Trustee).

10. TANGIBLE FIXED ASSETS

	Computer equipment £	Fixtures & fittings £	Total £
COST			
At 1 July 2021	3,060	2,421	5,481
Additions	-	-	-
Disposals	-	-	-
At 30 June 2022	<u>3,060</u>	<u>2,421</u>	<u>5,481</u>
DEPRECIATION			
At 1 July 2021	2,375	2,402	4,777
Charge for the year	126	12	138
At 30 June 2022	<u>2,501</u>	<u>2,414</u>	<u>4,915</u>
NET BOOK VALUE			
At 30 June 2022	<u>559</u>	<u>7</u>	<u>566</u>
At 30 June 2021	<u>685</u>	<u>19</u>	<u>704</u>

11. DEBTORS

	2022	2021
	£	£
Trade debtors	300	-
Prepayments	5,706	1,162
Other Debtors	13,116	10,026
	<u>19,122</u>	<u>11,188</u>

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2022

12. CREDITORS: Amounts falling due within one year

	2022	2021
	£	£
Trade creditors	482	-
Other creditors	-	-
Accruals	11,117	8,985
Deferred income	60,068	55,325
	<u>71,667</u>	<u>64,310</u>

Deferred income relates to EJSO royalties received in advance for the following period.

13. UNRESTRICTED FUNDS

Current year	Movement in resources:				Balance at 30/06/2022 £
	Balance at 01/07/2021 £	Incoming £	Outgoing £	Transfers £	
General unrestricted funds	<u>254,732</u>	<u>133,031</u>	<u>(107,143)</u>	<u>-</u>	<u>280,620</u>
Prior year	Balance at 01/07/2020 £	Incoming £	Outgoing £	Transfers £	Balance at 30/06/2021 £
General unrestricted funds	<u>194,062</u>	<u>138,735</u>	<u>(75,565)</u>	<u>(2,500)</u>	<u>254,732</u>

14. RESTRICTED FUNDS

Current year	Movement in resources:				Balance at 30/06/2022 £
	Balance at 01/07/2021 £	Incoming £	Outgoing £	Transfers £	
a) Alan Edwards Memorial Fund	5,569	9	(400)	-	5,178
b) Ronald Raven Prize Fund	2,469	7	(600)	-	1,876
c) Ronald Raven Travelling Fellowship Fund	25,417	33	(3,000)	-	22,450
	<u>33,455</u>	<u>49</u>	<u>(4,000)</u>	<u>-</u>	<u>29,504</u>

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2022**

14. RESTRICTED FUNDS

<i>Prior year</i>	<i>Movement in resources:</i>				<i>Balance at 30/06/2021</i>
	<i>Balance at 01/07/2020</i>	<i>Incoming</i>	<i>Outgoing</i>	<i>Transfers</i>	
	£	£	£	£	£
a) <i>Alan Edwards Memorial Fund</i>	5,968	1	(400)	-	5,569
b) <i>Ronald Raven Prize Fund</i>	569	-	(600)	2,500	2,469
c) <i>Ronald Raven Travelling Fellowship Fund</i>	28,414	3	(3,000)	-	25,417
	<u>34,951</u>	<u>4</u>	<u>(4,000)</u>	<u>2,500</u>	<u>33,455</u>

15. ANALYSIS OF NET ASSETS (between restricted and unrestricted funds)

<i>Current year</i>	<i>Tangible fixed assets</i>	<i>Other net assets</i>	<i>Total</i>
	£	£	£
Restricted funds	-	29,504	29,504
Unrestricted funds	566	280,054	280,620
	<u>566</u>	<u>309,558</u>	<u>310,124</u>
<i>Prior year</i>	<i>Tangible fixed assets</i>	<i>Other net assets</i>	<i>Total</i>
	£	£	£
<i>Restricted funds</i>	-	33,455	33,455
<i>Unrestricted funds</i>	704	254,028	254,732
	<u>704</u>	<u>287,483</u>	<u>288,187</u>

16. COMPANY LIMITED BY GUARANTEE

The company is controlled by its members. Every member of the company undertakes to contribute to the assets of the Company in the event of the same being wound up during the time he/she is a member, or within one year afterwards, for the payments of the debts and liabilities of the company contracted before the time at which he/she ceases to be a member and of the costs, charges and expenses of winding up the same, and for the adjustments of the rights of the contributors among themselves such amount as may be required not exceeding one pound.

17. RELATED PARTY TRANSACTIONS

There were no related party transactions that require disclosure during the year other than the reimbursement of expenses to Trustees, disclosed in Note 9.

Accounts

COMPANY REGISTRATION NUMBER : 7225131

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
UNAUDITED FINANCIAL STATEMENTS
FOR
YEAR ENDED 30 JUNE 2021**

Charity Number : 1136067



Edmund Carr LLP
Chartered Accountants
146 New London Road
Chelmsford
Essex
CM2 0AW

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2021

CONTENTS	PAGE
Company information	1
Trustees' annual report	2
Independent Examiner's report to the Trustees	10
Statement of financial activities	11
Balance sheet	12
Notes to the financial statements	13

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

COMPANY INFORMATION

YEAR ENDED 30 JUNE 2021

Charity Number 1136067

Company Number 7225131

Registered Office 35-43 Lincoln's Inn Fields
London
WC2A 3PE

THE TRUSTEES

The Trustees of the charity are also the directors of the charity.

The Trustees who served the charity during the year were as follows:

Mr Hassan Malik	President
Mr Zaed Hamady	Vice President
Mr John Whiting	Honorary Treasurer
Mr Michael Shackcloth	EJSO Representative
Professor Michael Douek	Honorary Secretary
Professor Jim Khan	Meeting Secretary
Professor Jayant Vaidya	Deputy Meeting Secretary
Mr Edmund Leung	
Professor Derek Manas	
Professor Richard Shaw	
Mr Aaron Quyn	(Appointed 23/11/2020)
Mr Anant Desai	(Appointed 23/11/2020)
Mr Riccardo Bonomi	(Resigned 23/11/2020)

BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT
YEAR ENDED 30 JUNE 2021

The Trustees have pleasure in presenting their report and the unaudited financial statements for the charity for the period ended 30th June 2021. The Trustees of the charity as shown on page 1 are also the directors of the charity.

Objectives and Activities

The Charity's objectives are:

To advance the science, practice, and art of surgical oncology for the benefit of patients with cancer; and to *promote research, training, and education in surgical oncology* for the benefit of the public, patients and the medical community, and to disseminate the useful results of that research appropriately.

The Association seeks to act as an umbrella organisation for those working in all surgical cancer specialties and cancer research. *In addition, the Society focuses on innovation in cancer care and support for future workforce training and development.* The Trustees pay due regard to the Charity Commission's guidance on public benefit when deciding what activities the Charity should undertake.

Portfolio of Awards

The Association takes great pride in its **portfolio of awards** to encourage our junior colleagues and to support their interest in the field of surgical oncology, its research and care of cancer patients. The Society continues awarding the following prizes at its annual scientific meeting:

- **Alan Edwards Memorial Prize** is awarded to the best poster presentation.
- **Ronald Raven Presentation Prize** is awarded to the best oral paper presentation.
- **BASO~ACS Presentation Prize**, formerly known as BJS Prize, is awarded to the best oral paper presentation. Due to the change of structure, the British Journal of Surgery Society (BJSS) discontinued to support this prize. In 2019, BASO Council agreed to sponsor this prize to ensure continuity to the BJS Paper Presentation Prize awarded at the BASO Meeting.
- **BASO Trainees (poster/oral presentation) Prize** is awarded to the best poster and oral paper presentations at the BASO Trainees Meeting. In addition, each year, BASO also presents the BASO Trainees Prizes in support of our trainee colleagues presenting papers at different surgical societies such as the Association of Surgeons in Training (ASiT), the Society for Cardiothoracic Surgery (SCTS), and the Association of Surgeons of Great Britain & Ireland (ASGBI).

To expand its commitment to all cancer-related professionals, BASO announced the following two new prizes at the 2019 BASO Annual Scientific Meeting:

- **BASO Trainees Audit/QIP Prize** to support and encourage trainees, those involved with audit and quality improvement with a view of improving care to patients, in particular, cancer patients.
- **BASO Multidisciplinary Prize** to recognise the work done by our Non-Medical Professional colleagues in supporting cancer patients. This unique award is designed to highlight any research, audit, quality improvement, health service provision/development, cancer patient pathway study, cancer survivorship study.

BASO Grants

BASO is expanding its portfolio of research grants to support cancer research and treatment.

BASO Raven Travelling Fellowship - (formerly known as Ronald Raven Travelling Fellowship) was endowed in 1993 by the Ronald Raven Trustees in memory of the Founder of the Association's Ronald W. Raven. BASO Continues to fund and award this fellowship, which has now increased to £3,000, each year to aspiring trainees to support them to expand their skills and experience in the surgical cancer treatment.

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2021

BASO (NIHR) Research Project Grant - BASO continues to be a non-commercial partner with the National Institute of Health Research (NIHR) and runs a successful annual research project grant scheme to assist surgeons in undertaking research projects related to surgically linked cancer care. This grant is open for discrete projects and a study awarded this grant is automatically eligible for consideration for the Clinical Research Network Support, thereby, is considered for being a portfolio study.

Endorsement of Regional Events

The Association aspires to engage with oncologists and Societies on the regional level. Via its network of Regional Representatives, BASO had been supporting various regional and national meetings. However, the participation has been limited during this accounting year due to the COVID.

Engagement with Medical Students

In the spirit of encouraging the future generation of surgical oncologists, the Association has opened its Trainees membership to Foundation Year Trainees and Medical Students those wishing to pursue surgical oncology. BASO aims to offer support with their surgical career by providing skills courses, mentoring sessions, and guiding surgical portfolio via our wealth of regional representatives.

The Society is actively engaging with undergraduate Medical Societies by sponsoring their annual meeting with BASO Prize and sponsored lectures.

BASO Trainees Group

BASO Trainees group continued growing their outlook and strengthened their links with trainees groups from across Europe. Through these collaborations, we encouraged trainees in tenets of research and clinical excellence in surgical oncology through the sponsored prizes at national specialty meetings. Our Trainees group continues to focus on research, academic training, and fellowships.

BASO @ the ACCEA Committee

In addition to its role within education and training, BASO is one of the selected few organisations that play a significant role in the assessment of and nominations for the Clinical Excellence Awards. BASO Council continues to sit on the ACCEA Award Committee and offers consultation to the ACCEA Focus Group.

BASO's contribution to NICE consultations and Cancer CRGs

The Society continues to make its mark and offers expert advice on numerous site-specific Surgical Cancer consultations as requested by NICE. Our Council members sit on various Cancer CRG's, offering expert advice.

Overall, the Society is maintaining healthy relations with all the surgical societies, the Royal Colleges, and exploring collaborative working opportunities.

Achievements and Performance

The Society has been proactive in dealing with the COVID-19 pandemic and its challenges have demonstrated the need for an umbrella organisation to speak with one voice. BASO is growing its membership, maintained steady finances and delivered a successful virtual meetings this year.

COVID-19

BASO is actively engaged in supporting our members and front-line clinicians to continue providing essential cancer surgery. BASO had issued the 'Strategy for Cancer Surgery sustainability and recovery in the COVID-19 pandemic' guidance to support its members.

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2021

An edited version of BASO's guidance was produced as a joint letter on behalf of ESSO and BASO to the Editor of the EJSO with a vision to expand our message to our colleagues in other European Countries. BASO's guidance was well received by our members and fellow colleagues, and was supported by numerous national and international surgical societies.

BASO also contributed to the NHS England document, 'Maintenance of Essential Cancer surgery for adults during the COVID-19 emergency'. BASO's recommendations, particularly, on screening, self-isolation of patients, and shielding of patients were included in the NHSE document.

BASO is also actively engaged with the CovidSurg-Cancer Study and is one of the key sponsors of this study. CovidSurg-Cancer is an international cohort study, designed by the team in Birmingham to assess the safety of surgery for all types of cancer during COVID-19 pandemic and the impact of pandemic in cancer delay and treatment pathways. BASO, as the non-commercial NIHR partner, is one of the Societies that offers a small surgical research grant to this study which would entitle it to be listed on the NIHR Portfolio.

The COVID-19 Pandemic has put immense strain on our healthcare system, however, our Trustees also believe that it has also led to innovation in a short period of time, and hope to continue providing support to our members and cancer community.

BASO Annual Meeting

2020 had been a challenging year and to support the ongoing education needs of its members and surgical community during these difficult times, BASO delivered its first virtual Annual Meeting. The meeting was themed on "Education" and was delivered under the leadership of our President Mr Hassan Malik and Professor Michael Douek as the Meeting Secretary.

The meeting was facilitated by an array of international speakers and panellists, all esteemed surgeons in the field of surgical oncology and had an attendance of 170 delegates. The feedback received from delegates and speakers was extremely positive, both about the content of the programme and the virtual organisation. The meeting generated a small profit.

94 abstracts were presented under oral or poster presentation sessions, and 8 prizes were awarded for best abstract presentations. It was however decided by the BASO Council to postpone the prestigious BASO Plenary Awards until 2021, to ensure that these awards were presented in person.

The key highlights of the programme were:

- Communication and Leadership skills in light of Covid-19.
- Tips on training opportunities due to Covid to help minimising effects of training loss.
- Debate Session: "This house believes cancer surgery should be done in specialised cancer hospitals".
- Informal "Breakfast session with BASO Council".
- Breast cancer IORT – where are we now? - session facilitated by international panellists.
- Global Surgery - the Covid effect facilitated by Prof Jiong Wu, Prof Richard Sullivan, Miss Rachel Hargest.
- Medico-legal issues in Covid times, presented an engaging presentation by Mr Robert Wheeler and Professor Peter Sagar.
- Virtual presentations of oral and poster abstracts.
- Live Q&A opportunities for delegates and panels.

The Association aspires to continue building on the success of this programme and making BASO meetings financially sustainable.

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)
YEAR ENDED 30 JUNE 2021**

European Journal of Surgical Oncology

The **EJSO**, co-owned by BASO and the ESSO continues to go from strength to strength with a rise in the quality of submission and article downloads. The 2020 impact factor were released earlier in June. The EJSO impact factor has increased to 4.424 from 3.959 from last year. (Follow link for more details: https://journalinsights.elsevier.com/journals/0748-7983/impact_factor). This is a remarkable jump in citations and credit must be given to the editorial team led by our past President Professor Riccardo Audisio (Editor in Chief).

Network and links with other organisations

The Association continues to grow its links with other specialties and to re-establish itself as the umbrella organisation for cancer surgeons, including forming membership links with other specialties and setting up partnerships for joint conferences in future.

Our **BASO Trainees Group** is also proactively expanding its partnership opportunities and has representation on the ASiT Council. BASO Trainees maintains a portfolio of Trainees Prizes of £100 each for the best surgical oncology presentations at the Annual ASiT Conference, and SCTS Annual Meeting held this year.

European Society of Surgical Oncology

BASO had signed a 'memorandum-of-understanding' with our European sister society **ESSO** to strengthen the affiliation between the two societies. BASO members did get affiliate membership to ESSO, however, with the updated agreement, BASO members now enjoy standard membership benefits of ESSO including reduced registration rates to the ESSO Annual conference, courses and training programmes. BASO members also get the opportunity to apply to an international career development programme and access to the membership restricted areas to the ESSO website. BASO individuals will now have the voting right at the ESSO General Assembly.

NIHR's Clinical Research Network

The Association also maintains its relationship with the NIHR's Clinical Research Network, and supports the 'Tomorrow's Leaders' programme which enrolls the future leaders in the field of surgical oncology and research. These leaders are encouraged to join our trainees' membership and are offered support to enhance their career in surgical oncology via short workshops, methodology training, research grant, etc.

National Clinical Guidelines

BASO continues to maintain a strong presence when National Clinical Guidelines are either developed or updated. BASO Trustees are appointed as the Specialist Advisors for the NICE's Interventional Procedure Programmes. Furthermore, BASO Trustees have been contributing to numerous consultations, and are active members of the different Cancer Commissioning Groups.

BASO@ UK Oncology Forum

BASO maintains an ongoing collaboration with the UK Oncology Forum and delivers a pan-tumour session every year. This national clinically focussed meeting is open to UK Cancer HCPs. And is free for BASO members to attend. In 2020, BASO hosted the 'BASO updates on multidisciplinary teams' session chaired by Mr Hamady, BASO Vice President. BASO Council aims to develop this collaboration further.

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2021

BASO Symposium @ Association of Surgeons of India Annual Conference

BASO delivered a joint BASO-ASI Symposium on '*Extremity Soft Tissue Sarcoma – A Therapeutic Quagmire*' at the ASI 80th Annual conference in December 2020. The conference was a well-received meeting with 6000 delegates in attendance. The session was co-chaired by Mr Anant Desai, BASO Trustee and ASI Panelists, and BASO talks were presented by Mr Andrew Hayes, Consultant Sarcoma Surgeon, and Mr Michael Parry, Orthopaedic Oncologists.

BASO Council is keen on developing further collaborative sessions at their future meetings

Cancer Services Committee

BASO~ACS continues chairing the RCSENG's **Cancer Services Committee**, and is now invited to offer expert advice towards the 'Future of Surgery' Commission, and has contributed on 'Restructuring of the MDTs', and GMC's proposal on Draft Credentialing Frame Work. As a surgical oncology society, we are actively engaged in decision making with organisations such as NICE, NCEPOD, Specialist Cancer CRG, the Royal College of Surgeons, and GMC.

BASO Publications

In addition, this accounting year, BASO also engaged with and contributed to:

- In December 2020, BASO worked with Health Awareness on the 2020 Innovations in Oncology campaign and produced an article on '**Digital surgery in the hand of the surgeon**'. This article was prepared by **Professor Jim Khan**, BASO Trustee and Dr Afsana Elanko, Director of Education.
- In June 2021, BASO contributed with the article '**Improving early cancer diagnosis with better detection**' on health Awareness on the 2021 Innovations in Oncology campaign, launched through the Guardian. The article was prepared by Mr Zaed Hamady BASO Trustee and Dr Afsana Elanko, Director of Education.

BASO Endorsed Meetings

This year, BASO endorsed the following events & meetings:

- Colorectal FRCS viva practice webinar: 21st May and 2nd July 2021
- ESSO HPB course: 8-10 Nov 2021

BASO~ACS continues to support and promote the development of cancer treatment, research, patient care, and education and training of our future generation of oncologists.

Financial Review

Membership

Membership of the Association remains stable during the course of the year. Membership subscriptions for 2020-21 continued to be kept intentionally low at £180 for full membership as the Association still holds high levels of reserves.

The subscriptions for the BASO Trainees for 2020-21 is also unchanged. As agreed at the 2017 AGM, BASO offers a 50% discounted fee to the Full Membership of the BASO~ACS for two years to a BASO Trainees member upon completion of training, provided they were the paying member of the Society for two consecutive years.

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2021

EJSO

The profits from the EJSO are offset against the cost of the membership subscriptions to the EJSO and these are included in the final reconciliation. A new Journal Publishing agreement between ESSO and BASO as owners, and Elsevier as publishers of the Journal, was made as of 9th December 2020. Elsevier paid a one-off signing bonus of £50,000 to both the Societies that was split 50:50 between BASO and ESSO.

This new agreement with added benefits and revenues for both the Societies began on 1st January 2021 and shall conclude on 31st December 2027. All the parties agreed to meet between Sep-Dec 2024 to review the performance of the Journal in light of expectations and overall market conditions. The updated agreement and the EJSO progression will secure the future income stream for BASO.

The Journal has generated a healthy profit for BASO~ACS in 2020 with an income of £65,367 after the deduction of BASO's membership subscription for the year. It is hoped that the EJSO will continue to grow under the editorship of Professor Riccardo A Audisio.

BASO Grants and Prizes

BASO (NIHR) Research Project Grant The 2020 BASO NIHR Research Project Grant of £3,000 was awarded to the CovidSurg- Cancer Study in April 2020. Two further applications were received in response to the 2020 call for submissions. It was agreed by the NC to merge these applications with the 2021 round of submissions, thereby, allowing trainees to submit their research work for BASO (NIHR) research grant.

Ronald Raven Travelling Fellowship Grant of £3,000 in total was awarded to:

Mr Neil Foden, SPR, Otolaryngology, South London Deanery

Laurence Glancz, ST8 Neurosurgery Trainee, Nottingham University Hospitals NHS Trust

BASO Trainees Prize were awarded at the following external meetings:

SCTS Annual Scientific Meeting

ASiT Annual Conference

BASO Annual Meeting 2020

BASO Trustees strongly feel that the Charity's continues fulfilling its objective by promoting and sponsoring advancement in research and education of surgical oncology through another successful meeting. The meeting was supported by industry sponsorship and had relatively lower costs. Also, to add to members' benefits, the BASO Council decided to offer the meeting FREE to BASO members. Overall the meeting generated a small profit.

The conference raised the Association's presence in the field of Cancer research and has helped engage with various organisations and groups; and offered a great networking platform for the BASO members; recruiting new members. The Association maintains a strong level of reserves and has acquired a new income stream with the EJSO; we can continue to invest our reserves in the promotion of education, training and research via our Annual Conferences. However, we do hope to move towards a cost-neutral financial structure.

Structure, Governance and Management

On 1st July 2010 a transfer was made from the unincorporated charity, BASO ~ The Association for Cancer Surgery, to the company limited by guarantee of the same name (Company number: 7225131, Limited by Guarantee and Registered as Charity No 1136067).

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2021

The company was incorporated on the 15th April 2010 when new Articles were established. Simultaneous transfers were made to the new Association of Breast Surgery, which is also a company limited by guarantee (Company No 7207053 and Registered as Charity 1135699).

The two Associations are thus legally independent of each other, with a service agreement between the two Associations to allow for the provision of a shared office and administration. Whilst the degree of separation has increased over time to allow both Associations to evolve and develop their individual identities, they share many goals and continue to work co-operatively together.

In May 2020 both the Associations separated their joint database and IT services, and agreed to retain historic records of joint members or those members of ABS who have attended BASO events and vice-versa. The service agreement is subject to periodic review to ensure its continuing relevance and fairness to both Associations. No further substantive changes are envisaged at this stage.

The Ordinary Members of the BASO~ACS National Committee (who are also Trustees and Directors) are elected by a ballot of the Membership of the Association, following a 'Call for Nominations'. Officer posts are notified to the Membership by a call for nominations, followed by a ballot of Trustees if there is more than one candidate. All Honorary Officers are also Trustees and Directors. All appointments are confirmed by the Membership at the AGM. BASO~ACS has National Committee meetings four times a year.

BASO also administer the Royal College of Surgeons of England's Cancer Services Committee, which meets three times a year and is chaired by the President of BASO~ACS. The main business of BASO~ACS is decided upon at its National Committee meetings. Decisions in-between times are made by phone or e-mail communication between the Honorary Officers, with day-to-day issues being dealt with by the Association Manager in liaison with the Honorary Officers. The Trustees/Directors regularly review the major risks that the charity faces and its reserve policy, combined with an annual internal audit of the controls over key financial systems, which are designed to provide sufficient resources in the event of adverse conditions. No major risks have been identified by the Trustees during the year.

The Trustees pay due regard to the Charity Commission's guidance on public benefit when deciding what activities the Charity should undertake.

Reserves Policy

BASO ~ ACS holds a sufficient reserve to allow the society to meet financial obligations in the event of a financial loss following an annual conference, to maintain the low level of conference fees for delegates and to obviate the need for increases in Membership fees. The level of reserves, and income from conferences and subscriptions, is crucial to the Association's work and objectives, and is monitored carefully to ensure a balance between a secure financial position for the Association and minimal costs to Members and potential Members.

Investment Policy

The Trustees have power under the Articles to invest funds in the same manner and subject to the same conditions as the Trustees of a trust are permitted to do by the Trustee Act 2000. The Association currently holds its reserves across three deposit accounts: BASO ~ ACS holds reserves in a Scottish Widows 90-day notice account; an instant access account with Lloyds TSB; and a further instant access account with Virgin Money. BASO Trustees are looking into new investment opportunities for the Association's reserves.

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2021

Plans for the Future

Growth of the core membership and the breadth of specialisms represented were set out as key aims for 2020-21. Whilst overall growth has not materialised, membership numbers have remained steady and the Trustees are actively seeking stronger links with other Associations, many of whom have been invited to nominate observers to Council meetings and to whose meetings we have offered to send observers, with the intention of improving communication and understanding in areas of common interest. Several of these Associations have expressed an interest and the Trustees look forward to reporting on progress in this area in future. The present Trustees themselves represent a broad cross-section of specialisms and so bring a welcome breadth of experience and perspective to the steering process.

BASO Trustees intend to establish affiliation support for smaller complex cancer surgical groups, offering them affiliation to BASO membership and endorsement of their meeting, etc., thereby expanding the Association's distinctive "brand" as the umbrella Society for all Cancer Surgeons.

To this end, in 2010-21 the Association has made significant contribution to different consultations as organised by NICE. The Trustees are actively developing collaborations with different Royal Colleges, Cancer Commissioning Boards/Reference Groups, Public Health England, GMC and many other interested parties with the aim – as always - of sharing knowledge, opening out debate and improving best practice for the benefit of cancer patients.

The Cancer Services Committee is currently reviewing the issue of 'complex surgical oncology training', 'Fellowship training recommendations for cancer surgery' and 'MDT revisions & review'. BASO has been invited to contribute to the 'future of surgery' commissioning of the RCS; and the CSC would ideally aspire to have direct representation on the RCS Council. The Cancer Services Committee has also been invited to be involved in setting the quality metrics for cancer surgery for the UK, in conjunction with CRUK and NCIN. Mr Hassan Malik, President is representing BASO on this Committee.

BASO Trustees have joined the Specialised Cancer Clinical Commissioning Group and using its wealth of experts are supporting service development in cancer surgery. BASO will continue to fund several small grants to support surgical oncology research in partnership with the NIHR. This initiative will foster increasing the breadth of surgical research as well as increasing recruitment of patients into NIHR portfolio studies.

BASO will broaden its grants and support to regional level meetings, and Student Surgical Societies. BASO Trainees membership is now open to Medical Students and Foundation Year Trainees, those interested in surgical oncology, with the aim to support their training and further education & career in cancer surgery.

As training and work pressures change with an ever-evolving healthcare service, our BASO Trainees group intends to improve the experience, training, and professional competence of surgical trainees with an interest in oncology, principally in academic and research matters.

This report has been prepared having taken advantage of the small companies exemption in the Companies Act 2006.

Approved by the Trustees on 21 November 2021 and signed on their behalf by:

John Whiting

**Mr John Whiting
Honorary Treasurer**

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES

YEAR ENDED 30 JUNE 2021

I report to the charity trustees on my examination of the accounts of the company for the year ended 30 June 2021 which are set out on pages 11 to 18.

Responsibilities and basis of report

As the charity trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Colin Barker

C A Barker FCA

Edmund Carr LLP
146 New London Road
Chelmsford
CM2 0AW

7 December 2021

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

**STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND
EXPENDITURE ACCOUNT)**

YEAR ENDED 30 JUNE 2021

		Unrestricted Funds	Restricted Funds	Total Funds 2021	Total Funds 2020
	Note	£	£	£	£
INCOME from:					
Charitable activities:					
Members' subscriptions		32,836	-	32,836	33,922
Scientific conference	2	4,110	-	4,110	26,945
Publications - EJSO		101,547	-	101,547	60,234
Other trading activities		47	-	47	400
Investments	3	195	4	199	947
TOTAL INCOME		<u>138,735</u>	<u>4</u>	<u>138,739</u>	<u>122,448</u>
EXPENDITURE on:					
Charitable activities					
Subscriptions - ESSO		7,366	-	7,366	6,445
Scientific conference	2	3,188	-	3,188	53,308
Publications - EJSO		11,180	-	11,180	11,701
Fellowships & awards	4	500	4,000	4,500	14,010
National Committee and support costs	5	53,331	-	53,331	79,990
TOTAL EXPENDITURE		<u>75,565</u>	<u>4,000</u>	<u>79,565</u>	<u>165,454</u>
NET INCOME/(EXPENDITURE)		63,170	(3,996)	59,174	(43,006)
Transfers between funds		(2,500)	2,500	-	-
NET MOVEMENT IN FUNDS		60,670	(1,496)	-	(43,006)
RECONCILIATION OF FUNDS					
Total funds brought forward		194,062	34,951	229,013	272,019
Total funds carried forward		<u>254,732</u>	<u>33,455</u>	<u>288,187</u>	<u>229,013</u>

The charity has no recognised gains or losses other than the results for the period as set out above.

The notes on pages 13 to 18 form part of these financial statements.

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
BALANCE SHEET
AS AT 30 JUNE 2021**

		2021	2020
	Note	£	£
FIXED ASSETS			
Tangible assets	10	704	494
CURRENT ASSETS			
Debtors	11	11,188	5,157
Cash at bank		340,605	265,367
		<u>351,793</u>	<u>270,524</u>
CREDITORS: Amounts falling due within one year	12	<u>(64,310)</u>	<u>(42,005)</u>
NET CURRENT ASSETS		287,483	228,519
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>288,187</u>	<u>229,013</u>
NET ASSETS		<u>288,187</u>	<u>229,013</u>
FUNDS			
Unrestricted	13	254,732	194,062
Restricted	14	33,455	34,951
TOTAL FUNDS		<u>288,187</u>	<u>229,013</u>

For the year ending 30 June 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006 and with the Financial Reporting Standard (FRS102) (effective 1 January 2019).

These financial statements were approved by the Trustees on 21 November 2021 and are signed on their behalf by:

Hassan Malik

MR HASSAN MALIK

John Whiting

MR JOHN WHITING

Company Registration Number: 7225131

The notes on pages 13 to 18 form part of these financial statements.

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2021

1. ACCOUNTING POLICIES

Basis of accounting

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

BASO - The Association for Cancer Surgery meets the definition of a public benefit entity under FRS102. Assets and Liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes. The financial statements are prepared in sterling, which is the functional currency of the charity, and rounded to the nearest £. The charity is a company limited by guarantee.

Going Concern

The Trustees have considered the impact of the Covid-19 pandemic in their assessment of the charity's ability to prepare accounts as a going concern. It is difficult to predict the impact on the charity and its funders, but having taken all the factors into account, the Trustees are of the opinion that the charity has sufficient resources to continue trading for the next 12 months from the date of signing these accounts.

Incoming Resources

Income from conferences held during the year is accounted for on an accruals basis. Membership subscriptions are recognised on receipt.

Resources Expended

All expenditure is accounted for on an accruals basis and includes VAT as the charity is not VAT registered. The majority of costs are attributable to specific charitable activities (ie conferences/awards). Fellowships and awards are accounted for in the period in which they are notified to the recipient. Governance costs are associated with the governance arrangements of the charity. Staff and office costs are recharged to the charity under the service agreement with ABS.

Debtors and creditors

Trade and other debtors are recognised at the settlement amount due. Creditors are recognised at their settlement amount.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and deposits.

Fixed Assets and Depreciation

Fixed assets are shown at historical cost. Expenditure on tangible fixed assets is capitalised. The cost of other items is written off as incurred.

Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:

Computer equipment	25% reducing balance
Fixtures & fittings	25% reducing balance

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS**

YEAR ENDED 30 JUNE 2021

ACCOUNTING POLICIES continued

Fund accounting

Funds held by the charity are either:

Unrestricted general funds – these are funds which can be used in accordance with the charitable objects at the discretion of the trustees.

Designated funds – these are funds set aside by the trustees out of unrestricted funds for specific future purposes or projects.

Restricted funds – these are funds that can only be used for particular restricted purposes within the objects of the charity.

**2. CHARITABLE ACTIVITIES
SCIENTIFIC CONFERENCE**

	Unrestricted Funds	Restricted Funds	Total Funds 2021	Total Funds 2020
	£	£	£	£
Income				
Fees	4,110	-	4,110	25,945
Lecture grants	-	-	-	1,000
	<u>4,110</u>	<u>-</u>	<u>4,110</u>	<u>26,945</u>
Expenditure				
Speaker expenses	-	-	-	6,172
Venue and catering costs	-	-	-	32,022
Other conference costs	3,188	-	3,188	15,114
	<u>3,188</u>	<u>-</u>	<u>3,188</u>	<u>53,308</u>

All conference income and expenditure in 2020 was unrestricted.

3. INVESTMENT INCOME

All of the charity's investment income arises from interest bearing deposit accounts.

4. FELLOWSHIPS & AWARDS

	Unrestricted Funds	Restricted Funds	Total Funds 2021	Total Funds 2020
	£	£	£	£
Ronald Raven Prize	-	600	600	600
Ronald Raven Travel Scholarships	-	3,000	3,000	3,000
Alan Edwards Memorial Fund	-	400	400	400
Other Awards	500	-	500	10,010
	<u>500</u>	<u>4,000</u>	<u>4,500</u>	<u>14,010</u>

In 2020 Other Awards were paid from unrestricted funds. All other prizes were paid from restricted funds.

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2021

5. NATIONAL COMMITTEE & SUPPORT COSTS

	Unrestricted Funds	Restricted Funds	Total Funds 2021	Total Funds 2020
	£	£	£	£
Staff salaries and pension costs	40,272	-	40,272	41,501
National committee costs	-	-	-	9,207
Service agreement charges	1,800	-	1,800	11,248
SOTA committee & meeting costs	-	-	-	1,731
Other support costs	5,344	-	5,344	7,436
Governance costs (note 6)	5,915	-	5,915	8,867
	<u>53,331</u>	<u>-</u>	<u>53,331</u>	<u>79,990</u>

All national committee and support costs in 2020 were unrestricted.

6. GOVERNANCE COSTS

	Unrestricted Funds	Restricted Funds	Total Funds 2021	Total Funds 2020
	£	£	£	£
Accounting and payroll services	4,025	-	4,025	3,871
Independent examination fee	<u>575</u>	<u>-</u>	<u>575</u>	<u>575</u>
Fees payable to independent examiner	4,600	-	4,600	4,446
Bank charges	416	-	416	438
Other professional fees	<u>899</u>	<u>-</u>	<u>899</u>	<u>3,983</u>
	<u>5,915</u>	<u>-</u>	<u>5,915</u>	<u>8,867</u>

7. STAFF COSTS AND EMOLUMENTS

Total staff costs were as follows:

	2021 £	2020 £
Wages & salaries	37,072	38,301
Pension costs (defined contribution scheme)	<u>3,200</u>	<u>3,200</u>
	<u>40,272</u>	<u>41,501</u>

Particulars of employees:

The average number of employees during the year was 1, (full-time equivalent - 0.8)
(2020 - 1 employee and 0.8 FTE)

No employee received remuneration of more than £60,000 during the period.

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2021**

8. NET OUTGOING RESOURCES FOR THE YEAR

	2021	2020
	£	£
This is stated after charging:		
Depreciation	168	167

9. TRUSTEES' REMUNERATION

None of the Trustees were paid any remuneration by the Association during the period.
Trustees are reimbursed reasonable expenses incurred when acting on behalf of the company.
Expenses totalling £188 were reimbursed to 1 trustee during the period (2020 - £4,015 to 9 Trustees).

10. TANGIBLE FIXED ASSETS

	Computer equipment £	Fixtures & fittings £	Total £
COST			
At 1 July 2020	2,682	2,421	5,103
Additions	378	-	378
Disposals	-	-	-
At 30 June 2021	<u>3,060</u>	<u>2,421</u>	<u>5,481</u>
DEPRECIATION			
At 1 July 2020	2,221	2,388	4,609
Charge for the year	154	14	168
At 30 June 2021	<u>2,375</u>	<u>2,402</u>	<u>4,777</u>
NET BOOK VALUE			
At 30 June 2021	<u>685</u>	<u>19</u>	<u>704</u>
At 30 June 2020	<u>461</u>	<u>33</u>	<u>494</u>

11. DEBTORS

	2021	2020
	£	£
Prepayments	1,162	-
Other Debtors	10,026	5,157
	<u>11,188</u>	<u>5,157</u>

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2021

12. CREDITORS: Amounts falling due within one year

	2021	2020
	£	£
Trade creditors	-	1,674
Other creditors	-	125
Accruals	8,985	5,791
Deferred income	55,325	34,415
	<u>64,310</u>	<u>42,005</u>

Deferred income relates to EJSO royalties received in advance for the following period.

13. UNRESTRICTED FUNDS

Current year	Movement in resources:				Balance at 30/06/2021 £
	Balance at 01/07/2020 £	Incoming £	Outgoing £	Transfers £	
General unrestricted funds	<u>194,062</u>	<u>138,735</u>	<u>(75,565)</u>	<u>(2,500)</u>	<u>254,732</u>
Prior year	Balance at 01/07/2019 £	Incoming £	Outgoing £	Transfers £	Balance at 30/06/2020 £
General unrestricted funds	<u>233,138</u>	<u>122,378</u>	<u>(161,454)</u>	<u>-</u>	<u>194,062</u>

14. RESTRICTED FUNDS

Current year	Movement in resources:				Balance at 30/06/2021 £
	Balance at 01/07/2020 £	Incoming £	Outgoing £	Transfers £	
a) Alan Edwards Memorial Fund	5,968	1	(400)	-	5,569
b) Ronald Raven Prize Fund	569	-	(600)	2,500	2,469
c) Ronald Raven Travelling Fellowship Fund	28,414	3	(3,000)	-	25,417
	<u>34,951</u>	<u>4</u>	<u>(4,000)</u>	<u>2,500</u>	<u>33,455</u>

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2021**

14. RESTRICTED FUNDS

<i>Prior year</i>	<i>Movement in resources:</i>				<i>Balance at 30/06/2020</i>
	<i>Balance at 01/07/2019</i>	<i>Incoming</i>	<i>Outgoing</i>	<i>Transfers</i>	
	£	£	£	£	£
a) <i>Alan Edwards Memorial Fund</i>	6,357	11	(400)	-	5,968
b) <i>Ronald Raven Prize Fund</i>	1,163	6	(600)	-	569
c) <i>Ronald Raven Travelling Fellowship Fund</i>	31,361	53	(3,000)	-	28,414
	<u>38,881</u>	<u>70</u>	<u>(4,000)</u>	<u>-</u>	<u>34,951</u>

15. ANALYSIS OF NET ASSETS (between restricted and unrestricted funds)

<i>Current year</i>	<i>Tangible fixed assets</i>	<i>Other net assets</i>	<i>Total</i>
	£	£	£
Restricted funds	-	33,455	33,455
Unrestricted funds	704	254,028	254,732
	<u>704</u>	<u>287,483</u>	<u>288,187</u>
<i>Prior year</i>	<i>Tangible fixed assets</i>	<i>Other net assets</i>	<i>Total</i>
	£	£	£
<i>Restricted funds</i>	-	34,951	34,951
<i>Unrestricted funds</i>	494	193,568	194,062
	<u>494</u>	<u>228,519</u>	<u>229,013</u>

16. COMPANY LIMITED BY GUARANTEE

The company is controlled by its members. Every member of the company undertakes to contribute to the assets of the Company in the event of the same being wound up during the time he/she is a member, or within one year afterwards, for the payments of the debts and liabilities of the company contracted before the time at which he/she ceases to be a member and of the costs, charges and expenses of winding up the same, and for the adjustments of the rights of the contributors among themselves such amount as may be required not exceeding one pound.

17. RELATED PARTY TRANSACTIONS

There were no related party transactions that require disclosure during the year other than the reimbursement of expenses to Trustees, disclosed in Note 9.